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ABSTRACT
Prostate cancer increases its incidence with age after men in their fifth decade as the
ratio of estrogen to androgen rises. Epidemiological studies indicated that high levels of
estrogens are associated with the high-risk ethnic groups for prostate cancer. Therefore
estrogens may be involved in prostatic carcinogenesis. It is widely believed that the actions
of estrogens are mediated by estrogen receptors. However, expression of estrogen receptor
in normal prostate and lesions of the gland was controversial. With the recent discovery of
second estrogen receptor (ER-P), this issue became more complicated and it needs to 
readdressed. In addition, the biological involvement of ER-p in human prostate remains to
be investigated. In this study, we demonstrated that human normal prostate epithelial cells
express ER-p but not ER-a, suggesting that estrogens act directly on these epithelial cells via
ER-p. Using RT-PCR analysis , the transcripts of ER-p were detected in our primary human
prostatic epithelial cell cultures that were derived from the ultrasound-guided peripheral zone
biopsies and the cells express two estrogen-regulated genes such as progesterone receptor
(PR) and pS2. Moreover, we had developed an ER-p antibody with fully characterizations
and used it for immunohistochemistry. Results indicated that ER-p protein is expressed in
the basal compartment of prostatic epithelium of the gland. Our findings lead to a new
hypothesis that estrogens directly act on human prostatic epithelial cells to modulate its
biological functions.
To investigate expression ofERs in prostate cancer, RT-PCR analysis was used. We
found that all three human prostate metastatic cancer cell lines, DU145 , PC-3 and LNCaP
express ER-p transcripts while ER-a mRNA expression only in PC-3 cells. Expressions of
PR and pS2 in these cell lines are various. LNCaP cells express both PR and pS2 mRNAs
but DU145 cells with only PR and PC-3 cells with only pS2. Our immunohistochemical
results on prostatic lesions revealed down-regulation of ER-p expression in high-grade of
dysplasia and carcinoma of peripheral zone of the prostate compared to their low-grade
lesions. This down-regulatiqn in high-grade carcinoma was verified in transcriptional level
by RT-PCR analysis on micro dissected normal epithelium and lesion samples of the gland.
In the metastasis, ER-p was found to be reactivated as we observed ER-p mRA expression
in prostate cancer cell lines.
Recent evidence suggests that ER-p may be antiproliferative factor for a protective
effect against the mitogenic activity of estrogens in breast and androgens in prostate.
Activation of the receptor may exhibit cell growth inhibition. We demonstrated that
antiestrogens (ICI- 182 780 (ICI) and 4-hydroxytamoxifenJ, raloxifene and phytoestrogen
(resveratrol), but not estrogens (17p-estradiol and diethylstilbestrol), inhibit growth of
DU145 cells which express only ER-p while PC-3 cells with both ERs showed growth
inhibition in response to estrogen and antiestrogen treatments. In DU145 cells, the ICI-
induced cell growth inhibition was prevented by blockade of ER-p expression using
antisense oligonucleotide. It indicated that the inhibition is mediated via ER-p associated
pathway. Using flow cytometry, we found that ICI-treatment could induce accumulation of
cells at GO- phase of cell cycle. Similarly, this Go- cell accumulation was also induced
by raloxifene in DU145 cells. For resveratrol, the treatment exhibited dual effects on cell
cycle distribution in DU145 cells. In the early treatment, resveratrol induced cell cycle
arrests at GO- phase. The prolonged treatment leads to S-phase cell cycle arrest.
To study the molecular mechanism of this ER-p associated cell growth inhibition
real-time RT-PCR analysis was used to semi-quantitate the transcript levels of tentative ER-p
regulated genes such as telomerase reverse transcriptase (TERT), survivin and thymidylate
synthase (TS) in the treated cells compared to those in control. Results demonstrated that the
treatment of ICI could down-regulate TERT and survivin mRNA expressions with dose-
dependent fashion. As the ICI-treatment, resveratrol downregulated expression levels of
TERT, survivin and TS in DU145 cells. Down-regulation of TS may be related to the S-
phase cell cycle arrest observed in the prolonged treatment of resveratrol.
Taken together, our findings support the concept that ER-p participates in cell cycle
regulation in normal and malignant prostatic epithelial cells. Presence of ER-p in basal cells
of the prostate acini indicates that the direct actions of estrogens may be involved in the
normal physiology of the gland. Loss of this receptor in primary prostate cancer and its re-
expression in metastasis suggests the roles of ER-p in the cancer progression. Activation 
the receptor by antiestrogen and phytoestrogen induced cell growth inhibition in prostate
cancer cells. The mechanism may be mediated by reduction of cell survival factors and
eventually decrease in cell viability and induction of cell cycle arests.
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CHAPTER I
INTRODUCTION
A. Prostate cancer epidemiology
Prostate cancer is the most common solid malignancy and the second leading cause of
cancer-related death in men in the United States. The American Cancer Society estimates that
in the United States , approximately 198 100 new cases of prostate cancer wil be diagnosed
and 31 500 men will die of prostate cancer durng the year 2001 and it will account for about
11 % of male cancer-related deaths. This cancer is extremely rare before age 40 but the
incidence increases with age. The rate of increase with age is greater than that for any other
cancer; rates increase at approximately the 9th- 10th power of age (Cook and Doll 1969). In
addition to age, epidemiological data shows that race is also an important risk factor for
prostate cancer. Afrcan-American men have the highest rates of prostate cancer in the world.
The rate is about 50-70% higher in Afrcan-Americans than in Caucasian-Americans (Ross
1996 , Paltz et a12000, Farkas et a12000, Hoffman et a12001 , Fowler et a12001 , Powell et al
2001). For Asian populations, native Chinese and Japanese showed the lowest prostate
cancer rates (Ross 1996, Watanabe et a12000 , Powell et a12001). The difference in incidence
was thought to be different detection strategies for prostate cancer. However
, after adjusting
for these diagnostic biases , there are stil significant differences among populations (Shimizu
1991 , Watanabe et al 2000, Powell et al 2001). Even though the incidence rates in Chinese-
and Japanese-Americans, compared to those in their homeland, increase after they
immigrated to America, their incidence rates are still much lower than that in Caucasians and
Afrcan-Americans (Shimizu 1991 , McCredie et al 1994, Whittemore et al 1995 , Angwafo
1998).
Microscopic prostate cancer (latent cancer) does not show significant differences
among ethnicities (Guileyardo et al 1980, Sakr et al 1995 , Sakr et al 2000, Selman 2000).
This asyndromatic cancer is frequently found in old men either at autopsy or after
cryoprostatectomy for a pathological condition of the bladder. It is small ( 5mm) and well
differentiated (Rich 1935 , Andrews 1949, Frans 1954, Sak et al 2000). The prevalence of
latent cancer suggests that prostate cancer initiation is likely due to endogenous factors. But
the promotion step leading to clinical cancer is predominantly influenced by exogenous
factors (Griffiths 2000). Endogenous estrogens (estrone and estradiol) and exogenous
estrogens such as phytoestrogens or xenoestrogens may affect this promotion step. However
very little is known about the importance of estrogens in prostate cancer.
B. Prostatic carcinogenesis
i. E idemiolo!!ical and clinical evidence
Epidemiological studies on hormonal status among populations with different degrees
of risk for prostate cancer demonstrated that high levels of estrogens were associated with the
high-risk group of population and therefore this steroid hormone might be one of the risk
factors (Hill et al 1984 , Ross et al1996, Henderson et al1988, De Jong et al1991 , Bosland
2000). Afrcan men shows higher levels of estrogens, such as estrone (Ross et al 1986 , Hill et
al 1984) and estradiol (Hill et al 1984) than Caucasian men among older populations. In
addition, De Jong et al found that serum level of estradiol were 15% higher in Caucasian-
Dutch men than in the Japanese men (Je Dong et al1991). Circulating estradiol levels were
found to be 37% higher in pregnant Afrcan-American women versus European-American
women; suggesting that Afrcan-American men are exposed to higher estrogen
concentrations than European-American before birth (Henderson et al 1988 , Bosland 2000).
However, population-based case-control studies (Nomura et al 1988 , Hsing & Comstock
1990, Com stocks et al 1993 , Gan et al 1996, Dorgan et al 1998) found no significant
differences in seru levels of estrogens between case patients and control subjects, except
for Barett-Connor et al (1990) who showed that the ratio increased linearly with an
increasing seru level of estradiol.
The incidence of prostate cancer rises in aging men at a time when the ratio of
estrogens to androgens is increasing up to 40%. Plasma levels of testosterone and other
androgenic hormones were shown to decrease due to declining testicular function as men age
(Vermeulen et al 1972, Gray 1991a, Gray 1991b, Kaufman et al 1998, Griffiths 2000).
Concurently, the prostatic epithelial cells but not stromal cells have lower levels of 5a-
hydrotestosterone (DHT) (Kreg et al1993) although the level in the whole prostate showed
no change (Barsch et al 2000) in accordance with the previous findings that DHT-forming
index (Vmax IK of 5a-reductase) decreased with age (Tunn et al 1988). In addition, an
increase in seru estrogens was found in aging men since aromatization of adrenal
androgens by peripheral adipose tissue was enhanced in the older men (Vermeulen et al
1972, Zumoff, 1982 , Gray 1991a, Gray1991b , Kaufman et al 1998 , Griffiths 2000). These
endocrine changes at mid-life are referred to as andropause. In the aged prostate, cellular
levels of estrogens (estradiol and estrone) are increased (Kreg et al 1993). Taken together
these observations indicate hormonal stimulations change in the aged prostate and suggest
these changes, especially increased estrogenic stimulation may be related to prostatic
carcmogenesis.
ii. Animal models
In animal models, administration of pharmacological doses of estrogens had been
reported to induce squamous metaplasia, as a proliferative alteration in epithelium, in
regressed prostates of castrated or hypophysectomized dogs (Leav et al 1978 , Merk et al
1986). Levine and colleagues (Levine et a11991) also found this estrogen-induced squamous
metaplasia in men who had benign prostatic hyperplasia and underwent medical castration
therapy with gonadotropin-releasing hormone agonist for more than 6 months. The
metaplastic change is initiated by the proliferation of basal cells which subsequently
differentiate into squamous cells (Leav et al 1978, Merk et al 1986, Levine et al 1991).
However, administration of estrogen in castrated guinea pigs induced hypertrophy of
secretory cells in the lateral prostate and increased the thickness of fibromuscular layer
possibly due to the increased cell proliferation of smooth muscle cells (Bruengger et al 1986
Tam et al 1991 , Tam & Wong 1991 , Ricciardelli et al 1994). Only the seminal vesicle
showed basal cell hyperplasia in the estrogen-treated castrated guinea pigs (Tam et al 1991
Tam & Wong 1991). Recently, exogenous administration of synthetic estrogen
(diethylstilbestrol) to intact mice elicited epithelial squamous metaplasia in prostate and the
effects were not related to androgen deprivation which was mediated via hypothalamic-
pituitar-gonadal axis (Risbridger et a12001).
When Wistar rats were exposed to estrogens prenatally and/or neonatally, the rats
developed squamous cell carcinoma in the prostate (Arai et al 1977, V orherr et al 1979 , Arai
et al 1983). Prenatal (McLachlan et al 1975) and neonatal (Pylkkanen et al 1991) estrogen
exposure in mice induced hyperplasia and dysplasia in prostates respectively. Recently, it
had been reported that a 50% increase in free-seru estradiol in male murine fetuses via a
maternal Silastic estradiol implant could induce prostate enlargement in the adult animals
possibly due to the increased androgen sensitivity (Vom Saal et al 1997). The enhanced
sensitivity to androgens in the adult prostate can be achieved with a low dose treatment of
estradiol immature male rat at 20-22 days of age. This permanent alteration of the prostate by
neonatal estrogen treatment was described as "estrogen imprinting" (Rajfer & Coffey 1978).
Later, a detailed study on estrogen imprinting on rat prostate was conducted by Prins (1992)
and demonstrated a decrease in weight, DNA contents and morphological changes in three
prostatic lobes (ventral, lateral and dorsal) of neonatal estrogenized rats. The hypoplastic
ventral and dorsal prostates showed an increase in interacinar stromal tissues, epithelial
hyperplasia in disorganized acini , luminal sloughing, apparent lack of differentiation as well
as a decrease in levels of androgen receptor with immunohistochemistr (Prins 1992) and
estrogen receptor p with semiquantitative in situ hybridization and RT -PCR analysis (Prins et
al1998).
Treatment with estradiol in intact Noble rats caused massive atrophy in the prostate
(Leav et al1989 , Ho & Yu 1995). This may be due to the suppression of LHRH stimulation
of the pituitar gland by the estrogens. As the results, the treatment indirectly decreases
testicular testosterone production. Since the prostate depends on androgens for its normal
growth and fuction, reduction of androgen level can lead to regression of prostate. A
combination of testosterone and estradiol induced prostate cancer in all Noble rats after 32
weeks of treatment (Noble 1977a, 1977b , Drago 1984, Leav et al 1989, Ho et al 1995
Bosland et al 1995). The cancers were derived from the periurethral , proximal ducts of the
dorsolateral and anterior prostates (Leav et al1989 , Ho & Yu 1995 , Bosland et al1995). This
can also be achieved in a shorter period of time by using an extremely high dose of
testosterone in combination with estradiol (Wong et al 1998). In fact, long-term androgen
(testosterone or 5 alpha-dihydrotestosterone) treatment alone was also able to induce prostate
cancer but the incidence was low (Noble 1977, Leav et al 1989, Bosland 1992, Ho & Yu
1995). Taken together, testosterone appears to be a weak carcinogen and the addition of
estradiol can enhance these carcinogenic effects on the prostate, indicating the importance of
estrogens in prostatic carnogenesis. Interestingly, the estradiol plus testosterone treatment-
induced prostate cancers in Noble rats were confined to the periurethral, proximal ducts of
the dorsolateral and anterior prostates but not in the periphery of the glands where dysplasia
developed in the acini (Leav et al 1989, Ho & Yu 1995, Bosland et al 1995). The
morphology of the acinar dysplasia is similar to human prostatic intraepithelial neoplasia
(PIN) which is considered to be a precursor of prostatic adenocarcinoma (Leav et al1989, Ho
& Yu 1995 , Bosland et a11995 , Bostwick & Montironi 1995 , Shin & Ro 1995 , Haggman et
al1997, Zlotta et al1999 , Alcaraz et al 2001). In addition to the Noble rats, it recently has
been reported that treatment with testosterone plus estradiol could also induce atypical
hyperplasia and carcinoma in a subset of mouse prostate tissues. This tissue has a
recombinant rat urogenital mesenchyme and is also deficient of retinoblastoma gene product
(Rb) (Wang et aI2000). The Rb-deficient prostate epithelia in these chimeric prostatic tissue
recombinants only showed a mild hyperplasia (Wang et a12000).
ii. Estro en rece tors ERs and estro en actions in normal rostate
It is widely believed that the actions of estrogens are mediated by an ER. Binding of
estrogens leads to conformational changes of the ER and the receptors recruit transcrptional
factors. The whole complex then binds to specific regulatory regions of DNA, promoting the
transcription of specific genes such as progesterone receptor and pS2 (Roberts 1988 , Clarke
1990). Evidence also indicates that estrogen receptors can regulate transcription through
protein-protein interactions between the receptors and other transcription factors such as AP-
1 and Sp- 1 (Webb et al 1995 , Paech et al 1997 , Saville et al 2000). Ligand binding studies
demonstrate both high affinity (type I) and low affnity (type II) estradiol binding sites in the
rat (Swaneck 1982 , Yu 1989) and in the human (Ekman 1983 , Donnelly 1983) prostate. The
type I binding site usually represents classical estrogen receptor (ERa) while the type II
binding site is still poorly characterized. Our laboratory had demonstrated the hormonal
regulation of the type II binding site in the rat prostate and the combined treatment of
testosterone and estradiol in Noble rats elevated its level along with an increase in wet weight
of the glands (Ho & Yu 1995). Inibition of this type II site with a specific antagonist (2
bis((3-methoxy- hydroxyphenyl)-methylene)-cyclohexanone) in intact adult mice showed
dose dependent reduction of prostatic weight (Markaverich & Alejandro 1998). Another
estrogen receptor (ERP) was recently cloned in rat prostate (Kuiper 1996) and also found in
human testis (Mosselman 1996). This ER subtype also shows high affnity to estrogens
similar to ERa. In sum, the normal prostate contains at least two high affnities (ERa and
ERP) and one low affnity (type II) estradiol binding sites.
Prior to discovery of ERp, immunohistochemical and in situ hybridization data
showed ER was expressed in the stroma of human prostate but not in epithelial cells (Seitz
and Wernert 1987, Konishi 1993 , Ehara 1995). Based on the cellular localization of ER
estrogens were thought to bind to stromal ER and exert its effects on epithelium only
indirectly via paracrine mediators such as stromal growth factors (Chung 1993 , Farsworth
1996, Chung & Davis 1996) (Figue 1A). It was supported by the findings that the level of
stromal basic fibroblast growth factor (bFGF) increased in the prostates of estrogen treated
rats (Bacher et al 1993). Also , estrogen, via estrogen receptor mediated pathway, enhanced
synthesis of epidermal growth factor (EGF) and insulin like growth factor -1 (IGF - 1),
mediating prostate enlargement in organ culture of rat fetal prostate (Gupta 2000). These
growth factors have been shown to stimulate growth of prostatic epithelium (Marengo &
Chung 1994 Udayakumar et al 1999). Administration of matrgel with EGF or bFGF
orthotopic ally in ventral prostates of adult rats increased the size and is related to stimulatory
growth of prostatic epithelium (Marengo & Chung 1994). Moreover, systemic administration
ofIGF- 1 can induce growth of the rat prostate (Torrng et al1997) and this factor also was
demonstrated to stimulate proliferation of epithelial cells from monkey prostate on
extracellular matrx substrate (Udayakumur et al1999).
However, the discovery of ERp in the prostatic epithelial cells weakens this
hypothesis. Estrogens may also have direct effects on epithelium of prostate (Figure 1B).
Although the expression and cellular localization of the two ERs has been examined
separately in the normal human prostate, the results remain inconclusive. Bohkoff and
colleagues found that ERa expression is restrcted to stromal and basal cells and is
undetectable in secretory luminal epithelial cells, and that none of stromal and epithelial
compartments shows ERp expression (Bonkoff et al 1999). In contrast to their findings , a
recent study on the human prostate (Royuela et al 2001) demonstrated that ERp is only
present in basal epithelial cells whereas ERa is expressed in stromal cells in normal prostate.
The human prostate is comprised of different anatomical zones (peripheral, transitional and
central zones) and they have different hormone receptor profiles determined by ligand
binding assays (Bashirelahi et al1983 , Bowman et al 1986 , Sciara et aI1995). The ratio of
androgen receptor to progesterone receptor was found to be higher in transitional and central
zones than in peripheral zone of the human prostate (Bashirelahi et al 1983). Uneven
distrbution of androgen receptor was also demonstrated in the human normal prostate
showing higher levels in the peripheral zone compared to those in other zones (Bowman et al
1986). Additionally, the transitional zone contains higher levels ofEGF and bFGF as well as
androgens than peripheral zones. Different zones of the prostate show histological
differences and the majority of prostate cancers are derived from the peripheral zone where
PIN lesions are frequently found while benign hyperplasia frequently develops in the
transitional zone (Greene et al 1995). In this study, we establish primary cultures of human
normal epithelial cells from the peripheral zone of the prostate for RT-PCR analysis to
determine the ERp mRA expression of in this particular cell type. We also develop ERp
specific antibody to immunolocalize this receptor and determine the ERp expressIOn II
different zones of human normal prostate.
iv. Estro en rece tors and estro en actions in rostate cancer
For human prostate cancer, expression ofER is still controversial. Some studies using
immunohistochemistry and in situ hybridization have shown no cancerous 
epithelial cells
expressing ER and demonstrated that ER 
mRNER protein positive cells were limited to
fibroblasts, myoblasts and smooth muscle cells (Wernert 1987
, Ehara 1995 , Hobisch et al
1997, Bodker et al 1999). In contrast, Konishi et al (Konishi 1993) detected a subset of
prostate cancers expressing ER using immunohistochemistry. With highly sensitive RT-
PCR
analysis, ER transcripts were able to be detected in two prostate cancer cell lines (PC-
3 and
LNCaP) derived from metastases (Carrba 1994, Castagnetta 1995), except Hobisch et al
(Hobisch et al 1997). Besides the question about ER 
expression in prostate cancer
, the
discovery of ERp complicated the question with which receptor isoform is 
predominantly
expressed. Because the DNA sequence recognized by the forward primer 
for RT-PCR in
Castagnetta s studies (Carba 1994 , Castagnetta 1995) was shared by both ERa and ERp,
careful primer-designs for RT-PCRs which can differentiate ERa and ERp are needed to re-
evaluate the expression of ERa and ERp in these two cell lines and other prostate cancer cell
-- -- -
lines. In addition, the ERa and ERp specific antibodies should be developed for
immunohistochemistr to re-examine the expression of ERa and ERp in human prostate
cancer tissues. This issue wil be carefully addressed in our study. Although expressions of
ERa and ERp were studied with ERa and ERp specific antibodies in human prostate cancer
the results remained inconclusive. Bonkoff et al found detectable level of ERa but not ERp
in 11% high-grade prostatic intraepithelial neoplasia, 43% and 61% prostate cancer with
Gleason grade 4 and 5 respectively, and 94% recurent adenomcarcinoma after hormonal
therapy (Bonkoff et al 1999), whereas Royuela and colleagues (Royuela et al 2001)
demonstrated that both ERa and ERp expressed in epithelial compartment of prostate cancer.
The stromal cells express ERa in the prostate but only a subset of prostate cancer showed
ERp expression in its stromal comparment (Royuela et al 2001). With ERa specific primer
sets for RT-PCR analysis, three prostate cancer cell lines (LNCaP, ARCaP and C4-2) were
studied and shown to express ERa mRA as well as its splicing variants (Ye et al 2000). For
the clinical specimens, Latil and colleagues (Latil et a12001) demonstrated detectable levels
of ERa and ERp transcripts in both normal and cancer tissues and down-regulation of ERp
mRA expression in one half of either localized or hormone-refractory tumors with real-time
quantitative RT -PCR assay. Because of cellular heterogenicity of prostate tissues
, the cellular
localization of ERa mRA expression and the down-regulation of ERp mRA still
remained to be elucidated. Our study with immunohistochemistry using ERa and ERp
- -=---
specific antibodies and RT -PCR analysis on Laser-capture-microdissected normal and
malignant prostate epithelial cells can provide more information about this issue.
C. Estrogen receptor beta (ERP) and ERa actions
The human ER was first cloned in 1986 (Greene et al 1986, Green et al 1986). After
10 years, the second ER was discovered in 1996 when PCR products, generated using
degenerate primers for conserved regions within the DNA- and ligand-binding domains of
nuclear receptors (Enmark et al 1994), were used as probes to screen a rat prostate cDNA
librar (Kuiper et al1996). The newly discovered ER was named as ERp and the original ER
was renamed as ERa (Kuiper et al 1996). The sequences of ERp in different species such as
human and mouse were also cloned (Mosselman et al 1996, Tremblay et al 1997).
Comparison on the amino acid sequences of these two receptors in rat, mouse and human
showed that ERp is highly homologous to ERa. They share 95-97% homology in their DNA-
binding domains and only 55-60% in the ligand-binding domains. The high varation was
found in their N- terminal AlB domains only showed about 16% homology (Kuiper et al
1996 , Mosselman et al1996 , Tremblay et al 1997). These differences may cause differential
cognate ligand profies and transactivational activities of these two receptors and the
unqueness in their biological functions.
Upon binding to ligands, estrogen receptors change their conformations and dimerize.
The whole complex with other transcriptional factors interacts with specific DNA region as
estrogen responsive element (ERE) to regulate gene expression. The ERE had been
extensively studied in promoters of vitellogenin in Xenopus and chicken, and prolactin
progesterone receptor as well as pS2 in mammals. It generally contains two repeats of core
sequence (AGGTCA) as palindromes (see review in Nardulli & Shapiro 1993). With RT-
PCR analysis on rat, tissue distribution of two receptors had been investigated and showed
- --
their expressions are quite different, i.e. moderate to high expression in uterus, testis
pituitar, ovary, kidney, epididymis , and adrenal for ERa and prostate, ovary, lung, bladder
brain, uterus, and testis for ERp (Kuiper et al 1997). Tissues such as kidney and adrenal
gland express predominantly or only ERa transcripts while ERp predominantly in lung,
spinal cord and prostate. Both receptors are highly expressed in ovary and uterus (Kuiper et
al 1997). Cells co-expressed ERa and ERp may form heterodimers upon binding to ligands.
As expected, gel shift assays demonstrated that two mouse ERs dimerize with each other and
bind to ERE (Pace et al 1997). The heterodimerization of human ERa and ERp was also
shown with mamalian two-hybrid system and the physical interaction of two receptors was
verified with GST-pulldown assay and co-immunoprecipitation assay (Pettersson et al1997
Ogawa et al 1998). In the presence of two ERs, they preferred forming heterodimer to
homodimer demonstrated in gel shift assays with both ERs binding to ERE (Pettersson et al
1997), possibly also in ERa and ERp co-expressed cells.
The actions of estrogen receptors on regulation of gene expression in molecular level
were extensively reviewed by Kushner and his colleagues (Kushner et al 2000). At ERE
estrogen receptor uses two transactivation functions (AF-1 and AF-2 in N-terminal domain
(NTDJ and ligand binding domain (LBDJ respectively) to recruit p160 coactivator proteins
such as SRC- , GRI1 and p/CIP (Figure 2, Kushner et al 2000) that bind to an integrator
molecule (CBP/p300). Crystallographic analysis indicated that nuclear receptor boxes of
p160 bind to hydrophobic cleft on the surface of LBD of a receptor (Shiau et al 1998).
Crystal strctures of LBD of ERp with ligands had been generated and were similar to ERa.
It forms hydrophobic cleft for binding of p 160 
co activators (Pike et al 1999). The
orientations of helix 12 of both receptors are related to the agonistic or antagonistic activity
of ligands at ERE. The orientation affects the binding of p 160 coactivator (Brzozowshi et al
1997, Shiau et al1998 , Pike et al1999). In contrast to AF-2 in LBD, the activity of AF- 1 in
NTD of two receptors is ligand independent and is activated via phosphorylation (Kato et al
1995 , Bunone et al 1996, Tremblay et al 1999). It binds to C-terminus of p 160 co activators
such as GRI1 and synergizes with the AF-2 (Webb et al 1998).
In addition to ERE, estrogen receptors had been demonstrated to also regulate genes
with promoter containing activation protein- 1 (AP- 1) sites (Gaub et al1990
, Umayahara et al
1994, Webb et al1995). Gaub et al found that ER transactivated ovalbumin gene promoter
with AP- 1 such as fos and jun proteins and showed that ER without DNA binding domain
(DBD) was still fuctional in this transactivation. Data suggested that direct ER interaction
with the target DNA is not required (Gaub et al1990). Although ER can regulate IGF-
1 gene
expression, the 600bp of the promoter contained no conventional ERE was still activated by
estrogens as target of estrogen regulation (Umayahara et al 
1994). Interaction between ER
and fos-jun complex was involved in this regulation
, via facilitating the binding of the
complex to AP- 1 site in this promoter region (Umayahara et al 1994). However
, ER without
DBD showed no activation but the direct ER binding to target DNA was not involved
(Umayahara et al 1994). In collagenase gene promoter
, Webb and his colleagues found that
ER with either tamoxifen or estradiol can activate this promoter at AP- site and
demonstrated DBD dependent and independent pathways of ER actions at 
AP- site (Webb
et al 1995). Tamoxifen induced activation is DBD dependent while estradiol induced one is
DBD independent (Webb et al 1995 , Kushner et a12000).
Estrogen activation at AP- 1 site was revealed to require the integrty of both AF-
and AF-2 with the genetic dissection of ERa domain (Kushner et a12000). The LBD of ERa
can strongly activate AP- 1 promoter in the presence of estrogens but not tamoxifen. Deletion
or mutation of AF-2 abolished this activation. The DBD in this estrogen activation was not
critical. Moreover, mutation of AF- 1 in ERa also severely decreased this activation at AP-
site (Kushner et al 2000). It indicated that the estrogen activation at AP-1 site is AF
dependent and DBD independent as well as ligand specific (estrogen but not tamoxifen)
(Gaub et al1990 , Kushner et a12000). In this pathway (Figue 3), the AP- 1 site recruits fos-
jun complex which stimulates transcription by recruiting CBP/p300 and associated proteins
such as p160 coactivators. The estrogens-ER complex trggers the p160 in the pre-existing
complex at AP- 1 site into a higher state of activity with both AF-1 and AF-2 and then
enhances the CBP/p300 transcriptional activity (Kushner et a12000).
In contrast, tamoxifen activation with ER at AP- 1 site was DBD dependent and AF
independent (Umayahara et al1994 , Kushner et a12000). Direct ER binding to AP- 1 site was
not involved (Umayahara et al 1994). Deletion of DBD in ER showed no activation in the
600 bp promoter of IGF-1 (Umayahara et al 1994). ERp in the presence of ICI- 182 780
raloxifene or tamoxifen but not estrogens can transactivate the promoter with AP- 1 site and
the action is completely independent of AF-2 (Webb et al 1999, Kushner et al 2000).
Moreover, the ERa without AF- 1 also showed this transactivation as ERp (Kushner et al
2000). It indicated that AF was non-essential in this DBD dependent activation. Based on the
finding that ER can bind to N-CoR only in the presence of tamoxifen (Jackson et al 1997
Lavinsky et al 1998), Kushner and his colleagues proposed the mechanism for this DBD
dependent and AF independent tamoxifen-ER activation at AP- 1 site (Figue 4) (Kushner et
al 2000). The complex of tamoxifen and ER at site where is away from AP- 1 promoter binds
to N-CoR and similar corepressors and recruits histone deacetylases (HDACs). It sequesters
HDACs away from AP- 1 site and sets free of the activity of histone acetylases in the fos-jun-
p160-CBP/p300 complex at AP- 1 site. As the results , it trans activates the promoter (Figure
4).
Tamoxifen with ER can also stimulate human qumone reductase (QR) gene
expression via electrophilic responsive elements (EpRE) (Montano & Katzenellenbogen
1997, Montano et al 1998). EpRE motif in human QR is comprised 12-0-
tetradecanoylphorbol- 13-acetate (TPA) responsive element (TRE) and TRE-like element as
well as AP- 1 site. Although there was AP- 1 site in human QR EpRE, ER regulation at EpRE
is not related to AP- 1 because TP A, a potent AP- 1 activity inducer (Piette et al 1988), canot
transactivate QR transcriptional activity (Montano & Katzenellenbogen 1997 , Montano et al
1998). Gel shift assay with rat glutathione-s-transferase-Ya EpRE which contained no AP-
site showed that major EpRE-interacting and activating proteins are not AP- 1 (fos-jun)
(Nguyen et al1992 , Favreau et a11993). Recently, hPMC2 (human homolog of Xenopus gene
(XPMC2) which prevents mitotic catastrophe J was identified to directly bind to the EpRE
and interact with ERs in yeast genetic screening and in vitro assays (Montano et al 2000).
The interaction with ERp is stronger than ERa (Montano et al 2000). Although the
mechanism for this ER regulation at EpRE is unkown, hPMC2 may act as a negative cell
cycle regulator by its regulation of QR transcriptional activity (Montano et al 2000). The
enzyme activates the anticancer quinones which enhance cellular levels of reactive oxygen
species (ROS) (Qiu et al1996). Then, the increased levels ofROS result in induction ofp21
and influence the cell cycle progression (Qiu et al1996).
D. Knockout mice models
Precise disruption or knockout of a particular gene in animals and examination of
their phenotypes can provide great insight into the roles of the gene in development and
normal physiology. ERa (Lubah et al 1993 , Dupont et a12000) and ERp (Krege et al1998
Dupont et al 2000) single knockout (ERaKO and ERPKO) and double knockout (ERapKO)
(Couse et al 1999, Dupont et al 2000) mice were generated and all showed no lethality of
ERa and ERp mutations. Their phenotypes were distinct (Couse et al 1999, Dupont et al
2000 , and see reviews in Couse & Korach 1999). Both sexes of ERaKO and ERapKO are
infertile while only ERpKO females are either infertile or subfertile with reduced litter size
and males are fertile (Lubah et al 1993, Krege et al 1998 , Dupont et al 2000). In female
reproductive tract, ERaKO develops hypoplastic uterus and vagina and no cyclic change
(Lubahn et al 1993) but the genital tract ofERpKO is normal (Krege et al1998). The lengths
of oviduct, uterus horns and vagina of ERapKO are normal while the diameter and thickness
are smaller than those in wild-type females (Couse et al 1999 , Dupont et al 2000). Ovares of
ERaKO adults are anovulatory and exhibit multiple hemorrhagic cysts and no corpora lutea
(Lubahn et al 1993, Dupont et al 2000) but underwent normal pre- and neonatal
development. The similar features of ovaries were found in ERapKO females. Strkingly, all
ERapKO ovaries contain fully differentiated Sertoli cells and exhibit follicle
transdifferentiation to structures resembling seminiferous tubules of the testis (Couse et al
1999, Dupont et al 2000). The ovaries of ERpKO mice show an increase in the number 
atretic follicles (Krege et al 1998) but an independent study on ERapKO mice found no
change and the ovares were macroscopically normal. In most of them, corpora lutea were
scarce or absent (Dupont et a12000). These findings indicated that the roles of both ERa and
ERp in proliferation of granulosa cells are crucial and that the presence of these two
receptors are required to complete the folliculogenesis in ovary. In the early stages of
follculogenesis, these receptors apparently are dispensable and can partially compensate
each other in the inactivation of either of these two receptors. It indicates that they show
some degree of functional redundancy. In ERaKO and ERapKO males , the testes are lack of
germ cells in the seminiferous tubules and show a marked dilation of straight tubules and rete
testis (Couse et al 1999 , Dupont et al 2000). The male reproductive tracts of ERpKO mice
are normal but the old animals develop hyperplasia in the prostate and the urnary bladder
(Krege et al 1998). However, these abnormalities were not found in another study and it
even showed no change in cell proliferation in prostates of 8 and 20 months old ERapKO
mice with labeling indices by Ki67 and BrdU immunostainings (Dupont et al 2000). In
contrast to ovaran growth, ERa may playa critical role and be indispensable in testis
development but not ERp. Due to the contradictory results of prostate and bladder in old
ERapKO mice (Krege et al 1998 , Dupont et al 2000), the precise roles of ERp in male
reproductive tract remain to be elucidated.
E. Estrogen therapy on prostate cancer
Hormonal therapy is the mainstay of treatment in patients with metastatic prostate
cancer. Medical castration is commonly accomplished with luteinizing hormone-releasing
hormone (LHR) analogues but these drugs are extremely expensive. Diethylstibestrol
(DES), a synthetic estrogen, has been shown to be a good alternative and cost effective
therapy (Byar 1973 , Pitts 1999, Seidenfeld et al 1999, Kitahara et al 1999, Bayoumi et al
2000). Theoretically, administration of DES causes suppression of LHRH stimulation of the
pituitary gland and indirectly reduces production of testosterone in testis. The serum
testosterone decreases to the anorchid level (Paulson 1984 , Pitts 1999 , Seidenfeld et al 1999).
As the results, the androgen-dependent prostate cancer regresses. Later, the patients will
develop androgen-independent cancer which is non-responsive to the treatments. However
DES may not be acting solely through the pituitary-gonadal axis as described above. DES
can suppress androgen-independent cancer growth in previously orchiectomized patients who
already had low level of serum testosterone. Several studies showed DES could directly act
on prostate cancer cells (Schulz 1990, Brehmer 1972 , Harley-Asp 1985 , Robertson 1996
Robertson et al (Robertson 1996) demonstrated direct cytotoxic effects of DES in prostate
cancer cells via an apoptotic mechanism and Harley-Asp et al (Hartley-Asp 1985) showed
DES induced metaphase arrest and inhibited microtubule assembly in prostate cancer cells.
In vitro studies also showed prostate cancer cells are sensitive to 17p-estradiol (E2) via an
ER-associated pathway (Carrba et al 1994, Castagnetta et al 1995). LNCaP , an androgen-
responsive prostate cancer cell line, shows a significant increase in cell proliferation by
treatment of E2. Although LNCaP cells expressed mutated androgen receptor (codon 868
threonine to alanine) which has increased affinity to estrogens (Trapman 1990, Veldscholte
- - ---- ,-!,,
1990), the presence of ER by immunohistochemistry and RT-PCR analysis and reversion of
E2-induced growth by antiestrogen (ICI- 182 780) suggested the biological response of
LNCaP cells to E2 is mediated via its own receptor (Castagnetta et al 1995). For the
androgen-nonresponsive prostate cancer cell line (PC-3), the response to E2 is totally
different from LNCaP. Instead of growth stimulation, E2 inhibited growth of PC-3 cells
probably via an ER-associated pathway (Carrba 1994). We carred out the comprehensive
study on the potential cell growth inhbition by estrogens such as DES and 17p-estradiol in
different prostate cancer cells including DU145 cells which had not been examined before.
F. Antiestrogens and prostate cancer
In the early 80s, Noble (Noble 1980a and 1980b) demonstrated the estrogen-
dependence of prostate cancer in Noble rat model. The tumor growth was inhibited by
removal of estrogen treatment and by tamoxifen, a non-steroidal anti estrogen, with
continuation of estrogen treatment. These findings prompted to the notion that using
antiestrogens could be the first arm of treatment on prostate cancer. Clinical trals on
tamoxifen with advanced stage prostate cancer patients were conducted (Glick et al 1982
Spremulli et al 1982). These studies showed tamoxifen to be a palliative treatment of the
disease. This may be partially explained by the estrogenic effects of tamoxifen (Rayter et al
1994, Eells et al 1990, Kedar et al 1994). However, in an Eastern Cooperative Oncology
Group trial, no patient responded to the treatment (Horton et al 1988). Moreover, the
estrogenicity of tamoxifen may increase the risk of cardiovascular disease similiar to the side
effects of DES treatment. Therefore, the potential for using antiestrogens as single arm or
- -
adjuvant treatment in prostate cancer was not fully explored. Later, ICI- 164 384 and ICI-
182,780 as steroid anti estrogens were developed and exhibited no estrogenic activity
(Wakeling et al 1991 , Osborne et al 1995). These chemicals can help us to address this
important issue that pure antiestrogens may be potential drgs for prostate cancer.
Experimental evidence suggests that their mechanisms of action may differ
signficantly from those of estrogens (Van Den Bemd et al1999, Zou et al1999 , Barkhem et
al 1998 , Paech et al 1997) and therefore may yield more favorable outcomes. Secondly, a
newly discovered ER subtype (ER-P) was found to be expressed at high levels in the
epithelial comparments of the rat prostate (Kuiper et al 1997 , Mosselman et al 1996 , Lau et
al1998 , Prins et al1998 , Chang and Prins 1999). Although ER-p shares high homology with
the classical ER (ERa), the two ER subtypes may regulate different sets of cellular fuctions
(paech et al 1997, Montano et a1 1998). Recent findings from an ERp knockout mouse
suggest that ERp may suppress proliferation and prevent hyperplasia in the rodent prostate
(Kege et al 1998). Taken together, these new findings raise an intrguing possibility that
ERp is expressed in normal and/or malignant human prostatic epithelial cell (PrEC) and
plays a role in mediating estrogen action in these cell types.
CHAPTER II
HYPOTHESIS
Since ERp was first identified in rat prostate and the presence of this receptor was
confirmed by microdissected rat epithelial cells in our previous study (Lau 1998), we
hypothesized that ERp may also be expressed in normal and/or malignant human prostatic
epithelial cell (PrEC). It may playa role in mediating estrogen action in these cell types.
Alteration of this receptor expression may be involved in prostatic carcinogenesis and its
expression level potentially correlates to the different stages of prostatic lesions. Although
the usage of tamoxifen in treatment of prostate cancer had been tested and apparently failed
the clinical trials which is possibly due to its parial estrogenicity, pure estrogen antagonists
(ICI 164 384 and ICI 182 780), selective estrogen receptor modulators, such as raloxifene
and phytoestrogens may yield more favorable outcomes since experimental evidence
suggests that their mechanisms of action possibly via ERp may differ significantly from
those of estrogens and tamoxifen. This has rekindled interests in using antiestrogens and/or
as therapeutic for prostate cancer.
CHAPTER III
EXPRESSION OF ESTROGEN RECEPTOR (ER)- a AND ER-p IN NORMAL AND
MAIGNANT PROSTATIC EPITHELIAL CELLS: REGULATION
- - 
METHYATION AND INVOLVEMENT IN GROWTH REGULATION
(Lau KM, LaSpina M, Long J, Ho SM. Cancer Research 60:3175-3182 , 2000)
A. ABSTRACT
The aim of the current study is to demonstrate normal and malignant prostatic
epithelial cells (PrECs) as targets for receptor-mediated estrogenic and antiestrogenic action.
Using an improved protocol we have successfully isolated and maintained highly enrched
populations of normal PrECs from ultrasound guided peripheral zone biopsies, individually
determined to be morphologically normal. Semi-quantitative reverse transcriptase-
polymerase chain reaction (RT-PCR) analyses were used to determine if transcripts of
estrogen receptor (ER)-a and those of ER-p were expressed in our normal PrEC primary
cultures, in a commercially available PrECs preparation (PrEC , Clonetics), in an
immortalized PrEC line established from a benign prostatic hyperplasia specimen (BPH- 1),
and in three prostatic cancer cell lines (LNCaP , PC-3 and DU145). Expression levels ER-a
and ER-p transcripts were related to those of two estrogen-responsive genes (progesterone
receptor (PR) and pS2J, at the message levels , to gain insights into the functionality of the ER
subtypes in PrECs. Interestingly, only transcripts of ER-p, but not those of ER-a, were
found in our primary cultues of normal PrECs, along with both PR and pS2 mRA. These
data strongly suggest that estrogen action was signaled exclusively via ER-p in normal
- -
. human PrECs. In contast, PrEC and BPH- 1 cells expressed both ER-a and ER-p
transcripts, and no PR nor pS2 mRA in PrEC and only minimal level of PR mRA 
BHP- 1. Among the three prostate cancer cell lines, LNCaP expressed ERp mRA along
with transcripts of PR and pS2 , DU145 expressed messages of ER-p and PR, and PC-3 cells
exhibited ER-a, ER-p and pS2 mRA. Thus , unlike normal PrECs , expression patterns of
these genes in malignant PrECs are more variable.
Treatment of prostate cancer cells with demethylation agents effectively reactivated
the expression of ER-a mRA in LNCaP and DU145 , and that of pS2 message in DU145.
These findings provide the first experimental evidence that ER -a gene silencing in prostate
cancer cells, and perhaps also in normal PrECs, is caused by DNA hypermethylation.
To evaluate the potential of using antiestrogens as prostate cancer therapies , we have
assesesed the growth inhibitory action of estrogens (estradiol (E2) and diethylstilbestrol
(DES)) and antiestrogens, (4-hydroxy-tamoxifene (40H-TAM) and ICI- 182 780 (ICI)) on
PC-3 and DU- 145 cells. In PC-3 cells, which express both ER subtypes, estrogens as well as
antiestrogens are effective inhibitors. On the contrary, in DU145 cells, which express only
ER-p, antiestrogens, but not estrogens, exhibit potency. By comparison, ICI is usually the
more effective cell growth inhibitor. Importantly, the ICI-induced antiproliferative effect
could be reversed by co-treatment of DU145 cells with an ER-p antisense oligonucleotide
hence lending additional support to a central role played by ER-p in antiestrogen action.
B. INTRODUCTION
Charles Huggins pioneered the use of the synthetic estrogen, diethylstibestrol (DES),
in the treatment of advanced prostatic adenocarcinoma (PCa) in the early 40' (Huggins and
Hodges 1941). The action of DES was thought to be mediated via a blockade of the
pituitar-testicular axis which effectively lowered circulating levels of androgen and caused
tuor regression (Paulson 1985). However, recent investigations have demonstrated that
DES exerts direct growth inhibitory effects on prostatic cancer cells via induction of mitotic
arest or apoptosis (Brehmer et al 1972, Hartley-Asp et al 1985 , Schulze and Claus 1990
Robertson et al 1996). Unfortunately, due to serious adverse effects induced by the
estrogenicity of DES (feminisation, exacerbation of heart failure, vascular complications
gynaecomastia, and impotence), the xenoestrogen has lost its attractiveness as a mainstay
treatment for advanced PCa (Ahed et al 1998). Clinical use of Tamoxifen (TAM), a
nonsteroidal estrogen mixed agonist/antigonist, was introduced in the 80s as an alternative to
DES in the treatment of PCa. It was better tolerated than DES , but only produced low
response rates (Glick et al1982, Spremull et al 1982 , Horton et al 1988 , Bergan et al 1995
Bergan et al 1999). It was therefore concluded that further investigation of Tam in advanced
. PCa treatment was not warranted. Of late, two recent developments have rekindled interests
in using anti estrogens as therapeutics for Pc. First, pure estrogen antagonists (e. g. ICI-
and ICI- 182 780; Wakeling et al 1991) and Selective Estrogen Receptor Modulators
such as raloxifene (Palkowitz et al 1997) have become available for clinical trials.
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Experimental evidence suggests that their mechanisms of action may differ significantly
om those of estrogens (Van Den Bemd et al 1999
, Zou et al 1999, Barkhem et al 1998
aech et al 1997) and therefore may yield more favorable outcomes. Secondly, a newly
discovered ER subtype (ER-P), was found to be expressed at high levels in the epithelial
compartments of the rat prostate (Kuiper et al 1997 , Mosselman et al 1996 , Lau et al 1997
Prins and Birch 1997 , Chang and Prins 1999). Although ER-p shares high homology with
the classical ER (ER-a), the two ER subtypes may regulate different sets of cellular functions
(Paech et al 1997, Montano et al 1998). Recent findings from an ER-p knockout mouse
suggest that ER-p may suppress proliferation and prevent hyperplasia in the rodent prostate
(Krege et al1998). Taken together, these new findings raise an intriguing possibility that ER-
P is expressed in normal and/or malignant human prostatic epithelial cell (PrEC) and plays a
role in mediating estrogen action in these cell types.
Knowledge of the distribution of ERp in normal and malignant human PrECs is
limited at this time. A recent study reported a lack of ERp expression in human prostate
tissues (Bonkoff et al 1999) while several preliminary reports noted expression of this
receptor subtype in basal epithelial cells of the human (Lau et al 1999a, Sinisi et al 1999
Taylor et al 1999). In this study, we reported that development of an effective method to
obtain and culture 'pure' or highly enrched populations of normal PrECs from needle
biopsies of the peripheral zone of the human prostate. Expression levels of ERa and ERp
transcripts in our primary cultues of normal PrECs were compared to those found in a PrEC
preparation obtained from a commercial source (PrEC , Clonetics), in an immortalized
PrEC cell line established from a benign prostatic hyperplasia specimen (BPH - , Hayward et
al 1995), and in three prostatic cancer cell lines (DU145 , PC-3 and LNCaP). Expression
levels of ER-a and ER-p in normal and malignant PrECs were then related to transcript
expression levels of two estrogen-responsive genes (progesterone receptor (PR) and pS2) to
gain insights into the fuctionality of the ER subtypes. Additionally, we have compared the
efficacy of two estrogens (DES and 17p-estradial (E2J) to those of two anti estrogens (4-
hydroxy-Tam (40H-TAM) and ICI- 182 780 (ICIJ) in inhibiting cell growth in PC-3 and
DU145 cells. An ER-p antisense oligonucleotide (ODN) was then used to demonstrate that
the antiestrogen-induced growth inhibitory effects on prostate cancer cells were mediated via
an ER-p signaling mechanism. Finally, we provided the first experimental evidence in
support of DNA methylation-mediated transcriptional inactivation of gene expression as the
mechanism ofER-a silencing in PrECs.
C. MATERIALS AND METHODS
i. Establishment of normal prostate epithelial cells (PrECs) in primary cultures
Tissue specimens used for generating primary cultures of normal PrECs were
obtained from patients undergoing transrectal ultrasound-guided biopsies of the ' prostate for
standard clinical indications. All patients contributing biopsy material were invited to
paricipate in a prospective tissue acquisition study approved by the local IR (approval was
granted to JL at the New England Medical Center, Boston, Massachusetts). Written
informed consent was obtained prior to biopsy from paricipating patients. From each
participant, one biopsy core was obtained from the peripheral zone of the prostate, placed on
a sponge pad soaked in sterile saline, a 1-2 mm section was excised from the mid-portion of
the core, and suspended in 5ml of culture medium (described below). The two remaining
ends of the core were inked at the ends opposite the sectioned mid-portion piece, placed in
10% formalin, and processed for histology. Histological examination of the end pieces of a
biopsy core allowed us to determine the histologic natue and the homogeneity of the core.
Only specimens judged to be histologically normal, with no hyperplastic or neoplastic tissue
contamination, were used to establish primary cultures of normal PrECs.
Each harvested tissue specimen was then washed three times with Han' s balanced
salt solution (HBSS) and cut into 5-7 smaller pieces. The pieces were suspended in 2ml
freshly prepared growth medium (see below) and transferred to a 60-mm Falcon culture dish
(Becton Dickinson, Lincoln Park, NJ) coated with Type I rat tail collagen (Collaborative
Biomedical Products, Bedford, MA). An epithelial cell selection medium (the growth
medium), previously reported (Bright et al 1997), consisted of keratinocyte seru-free
medium with 25 flg/ml bovine pituitary extract, 5 ng/ml epidermal growth factor, 2 mM L-
glutami , 10 mM HEPES buffer, PIS (100 U/ml Penicilin and 100 flg/ml Streptomycin),
5.5 fll/ml fugizone, 20 ng/ml cholera toxin and 1% heat-inactivated fetal bovine serum
(FBS) was used to obtain enrched populations of PrECs. All culture reagents were obtained
from Life Technologies (Grand Island, NY) except for FBS , which was purchased from
Sigma (St. Louis , MO). The culture was incubated at 37 DC in a 5% CO atmosphere without
disturbance for 7 days to allow epithelial cells to grow out of the tissue pieces. Culture
medium was then routinely replaced every 4 days until cell culture reached approximately
80% confluence. The cells were split once before they were used for RNA extraction.
In addition to primary cultures obtained from biopsy explants, a batch of normal
human prostate epithelial cells (PrEC ) were purchased from Clonetics Co. (San Diego
CA). The PrEC cells were cultured in the PrEGM medium supplemented with
SingleQuotsTM (Clonetics Co., San Diego, CA) according to the manufacturer
recommended protocol.
ii. Maintenance of established prostatic cell lines
All culture reagents were obtained from Life Technologies (Grand Island, NY) and
FCS from Sigma (St. Louis, MO) except otherwise specified. BPH- 1 (Hayward et al1995),
a nontumorigenic, SV 40-immortalized, highly differentiated human prostate epithelial cell
line was provided as a gift by Dr. Simon Hayward at the University of California at San
Francisco, Californa. This cell line was maintained in RPMI1640 with 10 mM HEPES, 1
mM sodium pyrvate, 2 mM L-glutamine, 4.5 g glucose/L and 1.5 g sodium bicarbonate/L
(ATCC, Rockvile MD) plus 5% heat-inactivated FBS, ITS+TM (Insulin-Transferrn-
Selenium mixture, Collaborative Biomedical Research, Bedford, MA), and PIS. Three
human prostate cancer cell lines (DU145 , PC-3 and LNCaP) were purchased from ATCC.
For routine maintenance, DU145 and PC-3 cells were grown in DMEM/- 12 supplemented
with heat inactivated FBS, 2 mM L-glutamine, 1 mM sodium pyrvate , 0. 1 M non-essential
amino acids, PIS , 0.05 mM p-mercaptoethanol (Sigma Co), and 1 % ITS+ TM LNCaP were
maintained in the same medium used for BPH- 1 except that ITS+ was left out from the
medium. All cell cultures were incubated at 37 C under a 5% C02 atmosphere.
ii. RNA isolation and reverse transcriptase-polymerase chain reaction (RT-PCR)
Total cellular RNA was isolated using RNA Stat-60 reagent (Tel- Test Inc.
Friendwood, TX) according to protocols provided by the manufacturer. The quality of each
total RNA sample was checked and controlled by the following steps: 1) measurement of optical
density, 2) rung of a denatug RNA gel capable of detecting possible RNA degradation, as
judged by the integrty and intensity of the 18S and the 28S ribosomal RNA signals, and 3)
conducting a semi-quantitative RT-PCR for the 18S ribosomal RNA at low cycle numbers. One
flg of total cellular RNA was reverse-transcribed using the GeneAmp RNA PCR kit (Perkin-
Elmer, CT) and 2fll of the resulting cDNA was used in each PCR.
Intron-spaning primers were either obtained from published literature or designed
usmg the Primer3 Output (http://ww . genome. wi.mit.edu/cgi-program
bin/primer/primer3.cgi). Primer sequences for GAPDH, ERa, ERp, PR and AR are given in
Table 1. All PCR conditions were optimized for quantification of relative message contents
under non-saturating conditions. Preliminary experiments were conducted to ensure linearity
for all semiquantitative procedures. Hot start PCR using AmpliTaq Gold DNA polymerase
(Perkin-Elmer, CT) was employed in all amplification reactions. The enzyme was activated
by pre-heating the reaction mixtures at 95 C for six minutes prior to PCR. This protocol was
chosen to minimize non-specific product amplification. The routine PCR program was 30
cycles of 1 min at 94 , 1 min at 60 C (anealing temperatue) and 1 
min at with the
following modifications: 1) amplification for ERp cDNA used an annealing temperature of
, 2) amplifications of ERa cDNA and AR cDNA were carred out at an annealing
temperature of 55 , 3) cycle-number for ERa cDNA amplification was set at 35, and 4)
GAPDH cDNA was amplified at 26 cycles. GAPDH cDNA levels served as a loading
control. Amplification of the correct sequence was verified by direct DNA 
sequencing of
each PCR product from at least two different samples.
iv. Treatment of DU145, PC-3 and LNCaP cells with demethylating agents
The three prostatic cancer cell lines were 
seeded at a density of 10 cells per ml
medium in 25 cmz culture flasks
, allowed to attach during a 24h period
, and exposed to two
demethylating agents separately. The demethylating agents were added daily in 
aqueous
solution. 5' azacytidine was added at final concentrations of2.5 flM and 5 flM and 5' aza-
deoxycytidine at 0.5 flM and 0.75 flM, respectively. Cultue medium was changed every
four days and cells were subjected to a total of 8 days of demethylating agent treatment. At
the end of the treatment period
, the medium was removed, and cellular RNA extracted for
RT-PCR.
v. Treatment of DU145 and PC-3 cells with estrogens/antiestrogens
Cells were seeded at a density of 5 X 10 per ml into 24-well plates (Falcon
, Becton
Dickinson Labware, Lincoln Park, NJ) in a final volume of 1 ml culture medium with 5%
charcoal-strpped FBS. Twenty-four hours following seeding, triplicate wells of cells were
treated in with 1 flM
, 10flM and 100flM of estradiol- 17P (E ), diethylstilbestrol (DES), 4'
hydroxytamoxifen (40H-TAM) or ICI 182 780 (ICI). Ez, DES, and 40H-TAM were
purchased from Sigma Co. (St. Louis, MO) and ICI was a generous gift from Zeneca
Pharaceuticals (Macclesfield, United Kingdom). Estrogens and antiestrogens were
dissolved in absolute ethanol (Sigma Co. , St. Louis , MO) and added to the media daily. Cell
cultures not treated with estrogenic compounds received absolute ethanol as a vehicle
control. Total additive ethanol concentrations never exceeded 0.2% throughout the culture
period. The cells were re- fed with freshly prepared medium every other day. At the end of a
day treatment period, cells in each well were trsinized and cell count determined by
direct counting using the Trypan blue exclusion method. All treatment experiments were
repeated at least three times to generate statistically relevant data.
vi. Treatment of DU145 cells with ICI and ERp antisense oligonucleotide (ODN)
DU145 cells (5 X 10 cells per well) were plated in 24 wells-plates (Falcon, Becton
Dickinson Labware, Lincoln Park, NJ). After allowing 24 hrs for cell attachment, cell
cultures were treated in triplicate with 1 flM ICI in the presence of 2.5 flM ERp antisense
sense or mismatch ODNs for 4 days. The ERp antisense ODN, an 18-mer, was designed to
recognze the first translation star site on the ERp mRA and its immediate 5' flanking
region (Table 2). The nucleotide sequence of sense ODN is complementary to those of ERp
antisense ODN (Table 2). Based on the sequence ofERp antisense ODN, 5 nucleotides were
scrambled to generate a mismatch ODN which retains the same GC ratio of the ERp
antisense ODN (Table 2). Both the sense and the mismatch ODNs served as controls for the
antisense ODN. In all three ODNs, the first and the last 3 nucleotides were
phosphorothioate-modified to increase their stability in cel/ulo. Number of viable cells in
each well was determined by direct counting using the Trypan blue exclusion method after a
day treatment period. At least three individual experiments were performed to obtained
statistically relevant data.
vii. Statistics
Statistical analysis was performed by using Student SYSTAT softare (Course
Technology, Inc. , Cambridge , MA). Data was analyzed by one-way ANOV A followed by
the Tukey post-hoc test and a 95% confidence limit was used for all comparsons among
treatment groups.
D. RESULTS
i. Expression of AR, ERp, PR and pS2 mRA, but not ERa transcripts, in normal
PrEC in primary cultures
Five primary cultures of normal PrECs (N4#6, N3#5 , N3#4 , N2#3 , N2#2) were
established in our laboratory from ultrasound-guided peripheral zone biopsies over a period
of 18 months. The biopsy cores were all judged upon histological examination to contain
only normal prostatic tissue with no BPH or cancerous foci contamination. The primary cell
cultues were all early passages (second or third), cobblestone in appearance, with no visible
fibroblast contamination. Semiquantitative RT-PCR analyses (Figue 4) demonstrated that
our normal PrEC cultues retained high levels of androgen receptor (AR) mRA expression
which usually disappeared in late passage normal PrEC primary cultues or in established
PrEC (Grant et al 1996). Interestingly, all five cultures of normal PrECs expressed uniform
levels of ERp RNA, and transcripts of the estrogen responsive genes, PR and pS2. In
contrast, expression of ERa mRA was noticeably absent in all five cultures even when high
cycle number PCR (::42 cycles) was used to amplify the cDNA. Interestingly, PrEC
(Clonetics Co), a commercially prepared normal PrEC culture, and BPH- , a SV-
immortalized prostatic epithelial cell line, expressed both ERa and ERp, but no PR or pS2
transcripts in PrEC and only minimal level of PR mRA in BPH -
ii. Expression of ERp, ERa, PR and pS2 mRA in prostatic cancer cell lines
All three prostatic cancer cell lines, DU145 , PC-3 and LNCaP , express ERp mRA
(Figure 4a c). In contrast, ERamRNA was expressed only in the PC-3 cells. Interestingly,
PR transcripts were detected only in DU145 and LNCaP cells, and not in PC- cells.
Messages of pS2 were found in PC-3 and LNCaP cells, but not in DU145 cells.
- accordance with reports in the literature, AR mRA expression was only noted in LNCaP
cells.
ii. Expression of ERa variant in prostate cell lines
When RT-PCR analyses were conducted for ERa mRNA semiquantification in
PrEC (Clonetics Co), BPH- 1 or PC-3 cells we noticed that, in addition to the expected
PCR product, a smaller PCR product was co-amplified (Figure 4a, b). Sequencing analysis
(data not shown) revealed that this smaller PCR product was derived from an ERa mRA
varant which had whole exon 2 deleted. We recently reported the co-existence of this ERa
mRA varant with wild-type transcripts in normal and malignant human ovarian surface
epithelial cells (Lau et al 1999b).
vi. Demethylation reactivates ERa and pS2 mRA expressions in DU145 cells and ERa
expression in LNCaP cells
Prior to exposure to demethylating agents, ERa and pS2 transcripts were not detected
in RNA samples prepared from DU145 cells (Fig. 4a c and Fig. 5). After the 8-day treatment
with 5' -aza-cytidine (2.5flM and 5flM) or 5' -aza- deoxycytidine (0.5flM and 0.75flM),
DU145 cells regained expression of both transcripts (Fig. 5). Interestingly, the absence of AR
mRA expression in DU145 cells was not reversed by treatment with demethylating agents.
Exposure of LNCaP cells to demethylating agents also reactivated ERa mRNA expression
(data not shown).
v. Effect of antiestrogens and estrogens on cell growth of DU145 and PC-3 cells.
Cell growth analyses showed that the growth of DU145 cells, which only expressed
ERP mRA, was adversely effected by the antiestrogens , ICI and 40H-TAM (Figue 6a &
6b). A dose-dependent inhibition of cell numbers was observed in cultures exposed to ICI
for 4 days when compared to control cultures treated with vehicle (absolute ethanol). A 40%
reduction 
(p 
~ 0.001) in the cell numbers was achieved with an ICI dose of 1flM. A similar
growth inhibitory response was observed when DU145 cells were treated with 40H-TAM.
However, cell number reduction achieved with 1flM of 40H-TAM was only around 25% 
~ 0.001). In contrast, exposure ofDU145 cells to estrogens (E2 and DES) did not affect cell
growth in 4-day exposure experiments (Figure 6c & 6d).
When PC-3 cells, which expressed transcripts of both ER subtypes , were exposed to
antiestrogens (ICI and 40H-TAM) a 25-30% reduction in cell growth was noted in cultues
treated with 1flM or 10flM of ICI, or with 1flM of 40H-TAM 
(p 
~ 0.001 , Figure 7a & b).
Furthermore, exposure of PC-3 cells to E2 at 1flM or 10flM concentrations also induced
inhibition of cell growth 
(p 
~ 0. 05 and ~ 0. , respectively; Figure 7c). Interestingly,
treatment with DES at the various concentrations did not elicit statistically significant cell
growth inhibition in PC-3 cells (Figue 7d).
vi. Reduction of ICI-induced cell growth inhibition by ERp antisense ODN.
Treatment of DU145 cells were with ICI at 1flM induced a 40% reduction in cell
number (Figure 7). Co-treatment ofDU145 cells with ICI and an ERp antisense ODN led to
restoration of cell number 
(p 
~ 0.001 , Figure 8) while co-treatments with an ERp sense ODN
or a mismatch ODN (Table 2) did not reverse the ICI-induced effects. These data support the
notion that the ICI-induced cell growth inhibition in DU145 cells is mediated via an ERp
signaling mechanism.
E. DISCUSSION
The roles played by estrogens in the neoplastic transformation of PrEC as well as in
PCa progression and treatment remain controversial. Exposure of human or rodent to
estrogens induces a proliferative lesion, squamous metaplasia, in their prostates (Sugimura et
al1988 , Yonemura et al1995 , Triche and Harkin 1971 , Levine et al 1991) while prolonged
treatment of Noble rats with androgen plus estrogen causes a high incidence of prostate
adenocarcinoma in the dorsolateral prostates of the treated anmals (Noble 1980, Drago 1984
Leav et al 1995 , Bosland et al 1995). Paradoxically, DES , TAM and other estrogens have
been used as treatment regimens for advanced metastatic PCa (Huggins and Hodges 1941
Ahed et al 1998, Glick et al 1982 , Spremulli et al 1982 , Horton et al 1988 , Bergan et al
1995, bergan et al 1999, Klotz et al 1999, Smith et al 1998). In addition to acting as
chemical castration agents , both estrogen and anti estrogen are believed to exert direct growth
inhbitory effects on prostatic cancer cells via induction of apoptosis or cell cycle arrest
(Brehmer et al1972, Harley-Asp et al1985 , Schulze and Claus 1990 , Robertson et al 1996
Landstrom et al 1996). Precisely how estrogens/antiestrogens elicit these actions remain
uncertain.
Traditionally, the actions of estrogens/antiestrogens are thought to be mediated via
the classical ER, the a-subtype, which has been localized to the stromal compartment and
basal epithelial cells of human and rodent prostates (Prins and Birch 1997, Bonkoff et al
1999 , Wernert et al1988 , Ehara et al1995 , Kirschenbaum et al1994, Hiramatsu et al1996).
Since ER-a is not expressed in the normal glandular epithelium of rat or human prostate
(Hartley-Asp et al 1985, Lau et al 1997, Bonkoff et al 1999, Ehara et al 1995
Kirschenbaum et al 1994 , Hiramatsu et al 1996 , Rohlff et al 1998), it is widely believed that
the action of estrogenlantiestrogen on normal PrECs is indirect, likely mediated via estrogen-
induced stromal factors. However, following the discovery of ER-p (Kuiper et al1997) and
its localization to the epithelial comparent of rodent prostates (Kuiper et al 1997, Lau et al
1997 , Couse et al1997) a distinct possibility has been raised that estrogenlantiestrogen could
influence PrEC function via an ER-p signaling pathway. However, at present, information
on ER-p in human PrECs is limited. Only one recent study (Bonkoff et al 1999) have
evaluated the expression pattern of ER-p transcripts and proteins in human prostatic tissues
and found non-detectable levels in both normal and diseased tissues. In contrast, the present
study unequivocally demonstrated expression of ER-p mRA in highly enrched or pure
human PrEC cultues established from peripheral zone biopsies. Furthermore, since ER-a
message was undetectable, but transcripts of two estrogen dependent genes, PR and pS2
were expressed in these cultues, these data strongly suggest that ER-p is the cellular
mediator of estrogen action in normal human PrECs. Of interest to note is that both ERa and
ERp mRA, but not PR or pS2 transcripts were expressed in a PrEC preparation purchased
from a commercial source (PrEC , Clonetics) and in the immortalized PrEC line, BPH-
with only minimal level of PR transcripts. The discrepancies between ER subtype, PR and
pS2 expression in our primar PrEC cultues and those observed in PrEC and BPH- 1 could
be due to the tissue of origin of these cell cultures/lines. In this regard, PrEC cultures
(Clonetics) are routinely prepared from whole prostates and BPH- 1 was derived from a
benign hyperplastic specimen (Hayward et al 1995) while our primary cultures were
established from ultrasound guided peripheral zone biopsies.
Issues relating to whether ER, and which subtype, is expressed in cancerous PrECs
remain unsettled. Several investigators (Carba et al1994 , Catagnetta et al1995) observed
ER-a expression in human prostate cancer cell lines, including LNCaP , PC-3 and DU- 145
while others (Hobisch et al 1998) did not. Similarly, observations on ER-a expression in
prostate cancer specimens were equally controversial. Bonkoff and co-workers recently
reported that ER-a expression was infrequent in low-to-moderate grade adenocarcinoma but
common in high grade and metastatic cancers (Bonkoff et al 1999). Conversely, Konishi
and associates noted the presence of ER-a immuno-positivity in well-differentiated
adenocarcinomas but not in poorly differentiated specimen (Konishi et al 1993). The latter
observation was supported by two additional studies that reported no ER-a expression in
lymph node and distant metastases (Hobisch et al 1998 , Castagnetta and Carba 1998).
These issues become more convoluted when expression pattern of ER-p is taken into
consideration. A lack of ER-p expression in human prostate tissues was reported by
Bonkoff and co-workers (Bonkoff et al 1999) while several preliminary reports noted
expression of this receptor subtype in dysplastic and cancerous tissues (Lau et al 1999a
Sinisi et al 1999, Taylor et al1999). Findings in the present study revealed that ERp mRA
was expressed in all three cancer cell lines (PC- DU145 and LNCaP) although, in
accordance with the literatue, the ERa message was only detected in PC-3 cells (Carrba et
al 1994). Unlike primary PrEC cultures, which uniformly expressed both PR and pS2
transcripts , PR mRA expression was only detected in DU145 and LNCaP cells while pS2
transcripts found in PC-3 and LNCaP cells. Hence, despite uniform expression of ER-p, the
expression patterns of ER-a, PR and pS2 among these prostatic cancer cell lines was
varable. Since transcription of PR and pS2 is well recognized to be regulated by estrogen
(Brown et al 1984, Stack et al 1988 , Savouret et al 1991) the loss of expression of these two
genes in some prostatic cancer cell lines suggest a deregulation of estrogen signaling in these
cells. A similar phenomenon has been observed in ovaran cancer cell lines which express
both ER subtype but no PR (Lau et al1999b).
Up till now, it remains unkown as to why prostatic epithelium expresses only ER-p
and not ER-a. In the present study, we demonstrated that treatment of DU145 and LNCaP
cells with demethylating agents reactivated ERa expreSSIOn in these cells. These data
provide the first experimental evidence in support of DNA methylation-mediated gene
silencing (Zingg et al1997 , Jones and gonzalgo 1997) as a mechanism ofER-a inactivation
in PrECs. In breast cancers , it had been shown that hypermethylation of the promoter region
of ER-a was associated with loss of expression of this receptor subtype in hormone
refractory cancers (Ottaviano et al1994, Ferguson et al 1995 , Marin et al1995 , Lapidus et al
1998). Although due to the fragile natue of PrECs in primary culture we had not subjected
them to demethylating agent treatment it is reasonable to assume that the same mechanism
transcriptional inactivation operates in ER-a silencing in the normal prostatic epithelium.
Interestingly, loss of pS2 expression in DU145 cells might also be linked to
hypermethylation-mediated transcriptional inactivation since exposure of this cell line to
demethylating agents revived pS2 expression. The pS2 gene encodes an 84 amino acid
cystein rich, secretary protein, which is widely expressed in estrogen sensitive tissues (Stack
et al1988). Its expression in prostate cancer specimens has been shown to be associated with
premalignant changes and neuroendocrine differentiation (Bonkoff et al1995 , Colombel et
al1999).
Different varants of ER-a transcripts are often found to co-exist with the wild type
- -
transcript in normal and malignant tissues (Hirata et al 1995 , Leygue et al 1996). These
varants, produced by alternative splicing, are whole exon deletion varants that may have
outlaw fuctions . In PC-3 cells , a previous study has demonstrated the expression of an
exon 4 deletion variant (Carrba et al 1994). In the curent study, we found an exon 2
deletion variant in PC- , BPH-1 and PrEC cells. Whether ER transcript variants have
fuctional or regulatory roles in prostatic cells is a topic of futue investigation.
Therapies for metastatic prostate cancers are limited. In addition to androgen ablation
therapies estrogens/anti estrogens have been used, singularly or in combination with other
modalities, for treatment of the disease. DES is an effective treatment therapy, however, its
estrogenicity induces signficant adverse effects in patients and have resulted in termination
of its use (Ahed et al 1998). In contrast, TAM, a non-steroidal anti-estrogen, is better
tolerated but produces little objective responses in multiple trals (Glick et al1982, Spremulli
et al1982 , Horton et al 1988 , Bergan et al1995 , Bergan et al1999). With the discovery of
ER-p as a new estrogen signaling pathway and the availability of pure anti-estrogen such as
ICIs (Wakeling et al 1991), it becomes appropriate to address the issue of whether pure
antiestrogens could be considered in the treatment of prostate cancer. In this study, we have
compared the efficacy of two estrogens (E2 and DES) an two antiestrogens (40H-TAM and
ICI) in inhibiting cell growth in two androgen refractory prostate cancer cell lines , PC-3 that
we found express both ER subtypes and DU145 that express only ER-p. Our results
demonstrated all four estrogenic/anti estrogenic compounds , at relatively low doses , exerted
antiproliferative effects on PC-3 cells , with antiestrogens exhibiting greater potencies. 
the contrary, DU145 responded only to antiestrogens. In both cases, ICI was found to be
more potent than 40H-TAM as a growth inhibitor. Importantly, the antiestrogen-induced
growth inhibitory response in DU145 cells was reversible by co-treatment with an ER-p
antisense ODN, although the effciency of the antisense to block ERp protein synthesis in the
treated cells was not demonstrated in our study. Furher experiments were warranted to
verify the involvement of this ICI-induced growth inhibition in DU145 cells. Taken
together, these findings raise several significant implications. First, it is apparent that the
estrogen/anti estrogen-induced antiproliferative action on prostatic cancer cells is ER subtype
dependent. It supports the prediction for the antiproliferative action of ERp by Gustafsson
(Reynolds 1999). Secondly, since ICI consistently expresses a higher potency it may be
better suited to be used in prostate cancer treatment. In clinical trials for breast cancer
treatment, this compound has demonstrated high effcacy and low toxicity (England and
Jordon 1997). Finally, our data have provided the first demonstration that
estrogen/antiestrogen action in prostatic cancer cells could signal via an ER-p pathway.
Since ER-p selective ligands have recently been reported (Montano et al 1999), this
development raises the likelihood of using receptor subtype ligands as cancer therapeutics in
the future.
Webb and his colleagues found that estrogen receptors with either tamoxifen or
estradiol can transactivate the promoters with AP- 1 site and demonstrated that tamoxifen
induced DNA binding domain (DBD) dependent activation while the estrogen-induced
activation is DBD independent (Webb et al 1995 , Kushner et al 2000). ERp in the presence
ofICI- 182 780, raloxifene or tamoxifen but not estrogens can transactivate the promoter with
AP- 1 site and the action is completely independent of AF-2 (Webb et al1999 , Kushner et al
2000). In the DBD dependent activation of AP-1 site, the potency of ICI is higher than that
of TAM and estrogens showed no effects on this activation (Webb et al 1995 , Kushner et al
2000). In our study, ICI inhibited about 40% of cell growth while TAM induced 20% cell
growth inhibition, indicating the higher potency of ICI on cell growth inhibition in DU145
cells as compared to TAM. In addition, no effects on cell growth was found in the estrogen
treatments. Therefore, the ICI may transactivate AP- 1 site via DBD dependent pathway to
modulate the cell growth in DU145 cells.
In sumary, this paper has demonstrated that human normal PrECs express
exclusively ER-p and likely signal via this receptor subtype for estrogen/antiestrogen action.
On the contrary, prostatic cancer cells exhibit a more varable pattern of ER subtype
expression and their responses to individual estrogen or antiestrogen will depend on the ER
subtype(s) expressed in the cells. Significantly, we provide the first experimental evidence
that ER-a gene silencing in prostate cancer cells , and perhaps also in normal cells, may be
caused by DNA-hypermethylation. Overall, data from this paper lend support to the notion
that ER-p, plays a central role estrogen/antiestrogen signaling in normal and malignant
human PrECs.
CHAPTER IV
COMPARTIVE STUDIES OF ESTROGEN RECEPTOR-BETA, -ALPHA AND
ANDROGEN GLANDS,RECEPTOR NORMAL HUMAN PROSTATE
DYSPLASIA, AND IN PRIMARY AND METASTATIC CARCINOMA.
(Leav Lau KM, Adams JY, McNeal JE, Taplin ME, Wang J, Singh H, Ho SM. American
Joural of Pathology 159:79- , 2001)
A. ABSTRACT
An antibody specific for estrogen receptor-p (ER-P), was used to immunolocalize the
receptor in histologically normal prostate, dysplasias (prostatic intraepithelial neoplasia-PIN),
primary carcinomas and in metastases to lymph nodes and bone. Comparsons were made
between ER-p, estrogen receptor -a (ER-a) and androgen receptor (AR) immunostaining in
these tissues. Concurrently, transcript expression of the three steroid hormone receptors was
studied by RT-PCR analysis on laser microdissected (LCM) samples of normal prostatic
acini , dysplasias and carcinomas.
In normal prostate, ER-p immunostaining was exclusively localized in the nuclei of
basal cells and to a lesser extent stromal cells. ER-a staining was only present in stromal cell
nuclei. AR immunostaining was variable in basal cells but strongly expressed in nuclei of
secretory and stromal cells.
Overall, prostatic carcinogenesis was characterized by a loss of ER-p expression at
the protein and transcript levels in high-grade dysplasias , its reappearance in grade 3 cancers
and its diminution/absence in grade 4/5 neoplasms. In contrast, AR was strongly expressed in
all grades of dysplasia and carcinoma. Since ER- is thought to fuction as an inhibitor of
I -
prostatic growth, androgen action, presumably mediated by fuctional AR and unopposed by
the receptor, may have provided a strong stimulus for aberrant cell growth. With the
exception of a small subset of dysplasias in the central zone and a few carcinomas, ER-
stained cells were not found in these lesions.
The majority of bone and lymph node metastases contained cells that were
immunostained for ER-p. Expression of ER- in metastases may have been influenced by
the local microenvironment in these tissues. In contrast, ER-a stained cells were absent in
bone metastases and rare in lymph nodes metastases. Irespective of the site, AR positive
cells were found in all metastases. Based on our recent finding of ER-p mediated growth
inhibition of prostate cancer cells in vitro (Lau et a12000), the presence ofER-p in metastatic
cells may have important implications for the treatment of late stage disease.
B. INTRODUCTION
Cellular differentiation and proliferation of prostatic epithelium has long been
considered to be primarily mediated by androgens. In this regard, the majority of prostate
cancers are initially responsive to antiandrogenic therapies but eventually become refractory
to this form of treatment (Grayhack et al 1987, Kozlowski et al 1991). The first medical
antiandrogenic therapy used to treat men with prostate cancer employed estrogens, primarily
acting indirectly at the hypothalamic level to down- regulate circulating levels of androgens
with resultant degenerative effects on neoplastic cells (Huggins and Hodges 1941).
Paradoxically, despite its use as an antiandrogen, pharacological doses of estrogens can
also induce a marked proliferative alteration of prostatic epithelium termed squamous
metaplasia, in the glands of a varety of mamals including humans (Helpap and Stiens
1975 , Leav et al1978 , Merk et al1986 , Mawhinney and Neubauer 1979 , Levine et al1991).
The metaplastic change is initiated by the proliferation of basal cells which subsequently
differentiate into squamous cells (Leav et al 1978, Merk et al 1986, Levine et al 1991).
Importantly, it has been shown that estrogens alone can directly induce squamous metaplasia
in the regressed prostates of castrated or hypophysectomized dogs (Leav et al 1978 , Merk et
al 1986).
Despite the proliferative effects of estrogens on basal cells which are the purported
progenitor cells of prostatic glandular epithelia (De Marzo et al 1998), the role that the
hormone may play in the abnormal growth of the gland remains undefined. Results from a
number of epidemiological (Ho et al1997 , Bosland 2000) and experimental studies (Ho et al
1997 , Bosland 2000 , Santti et al 1994, Pykkanen et al 1996 , Leav et al 1988 , Bosland et al
1995) have suggested that estrogens may be involved in this process.
Effects of estrogens on target tissues are now known to be mediated by ligand-
specific transcription factor receptor proteins termed estrogen receptor -a and -p (ER-a and
ER-P) (Kuiper et al1996 , Mosselman et al1996, Tremblay et al1997 , Bhat et al1998). The
two isoforms have highly homologous in DNA-binding domains but significant differences
in acid amino sequences are found in the N-terminal, hinge region, ligand binding and F
domains (Mosselman et al1996). Both receptors are present in many of the same tissues but
differences in organ and tissue distribution as well as in levels of expression has been
reported for the two isoforms (Mosselman et al 1996 , Enmark et al 1997 , Kuiper et al 1997).
In this regard, ER-p mRA was found to be predominant over the ER-a isoform in the rat
prostate (Kuiper et al 1996) and it was also present in human gland albeit in lesser amounts
than in the testis (Mosselman et al 1996). ER-p and ER-a were also shown to bind to the
same ligands with different affnity (Kuiper et al 1997). In addition, following binding to
estrogens and antiestrogens , the two ER-isoforms utilize different enhancer elements such as
estrogen responsive element (ERE) and API sites in promoter regions of gene (Paech et al
1997). Taken together, these two studies suggest that ER- and - may mediate diverse
downstream effects (Paech et al1997 , Enmark and Gustafsson 1999, Gustafsson 1999).
Although the precise biological fuction of the two ER-isoforms in the prostate is
curently undefined (Chang and Prins 1999), in one study, ER-p knockout mice have been
reported to develop age-related prostatic hyperplasia, which suggests that the receptor may
act to inhibit abnormal growth of the gland (Krege et al 1998). In support of this concept
Poelzl et al (2000) have recently reported that ER-p, but not the a isoform, specifically
interacts with MAD2 the cell cycle spindle assembly checkpoint protein. Moreover, Lau et al
(2000) demonstrated that antiestrogens downregulate cell proliferation in human prostate
cancer cells that only express the ER- isoform. ER-p has also been found to be involved in
mediating estrogen/anti estrogen induction of quinone reductase via its interaction with the
electrophile/antioxidant response element (EpRE) in the promoter region of the gene
(Montano et al 1998). It has therefore been proposed that the receptor may be involved in
regulating the expression of antioxidant enzymes and thus playa role in protecting cells
against oxidative injur Chang and Prins 1999 , Montano et al1998).
Prior to the discovery of ER-p, ER-a antibodies or in situ hybridization were used to
study estrogen receptor localization in normal, hyperplastic and carcinomatous human
prostate tissues (Wernert et al 1988, Schulze et al 1990, Ehara et al 1995) . Most of these
reports showed that ER-a was predominately localized in the stroma of normal and
hyperplastic prostates with the occasional detection of the receptor in basal cells and
glandular epithelia. With the exception of one recent study (Bonkoff et al 1999), ER-a
immunostaining was not detected in primary or metastatic prostate cancers. To date, there is
only one published report of ER-p localization in the normal human prostate (Taylor and
Azzawi 2000). Similarly, one study has reported ER-p protein expression in human breast
tissues using an antibody developed by the investigators (Fuqua et al1999).
In the current investigation, we developed a novel antibody directed against the F
domain ofER-p, a region that has no homology with the a receptor (Mosselman et al 1996).
We demonstrate that this antibody does not cross react with ER- . This reagent was used to
immunolocalize the receptor in morphologically normal glands from the 3 anatomic zones of
the prostate, dysplasia (also termed prostatic intraepithelial neoplasia -the purorted
precursor of carcinoma) (McNeal 1993 , Bostwick 1995), and in primary and metastatic
carcinoma. Laser-capture microdissection/reverse transcription polymerase chain reaction
(LCMlT-PCR) was also used to study transcript expression of the receptor in dysplastic
lesions and in grade 3 and 4/5 carcinomas. Results from the studies of ER-p were compared
with the concomitant investigation of androgen receptor (AR) and ER-a expressions at both
immunohistochemical and transcript levels. In this maner, changes in the expression of any
of the three receptors could be evaluated as to how they may relate to the development and
progression of prostatic carcinoma. Differences in receptor expression between grades 3 and
4/5 were emphasized in our study since it has recently reported that the percentage of grade
4/5 carcinoma in a prostatic neoplasm is highly predictive of disease progression (Stamey et
al1999).
To our knowledge , our report is the first where antibodies specific for ER-p, ER-a
and AR were used together with LCM /RT-PCR to compare the expression of these receptors
in normal human prostate, dysplastic lesions and carcinoma.
We find that within the epithelial comparment of normal human prostate, ER-
predominately localized in basal cells and to a lesser extent stromal cell nuclei. In contrast
ER- was rarely detected in basal cells but was strongly expressed in stromal cell nuclei.
Expression of the receptor was diminished in high-grade dysplasia and grade 4/5
carcinoma of the peripheral zone. A similar trend was found at the transcript level in
microdissected tissues. The majority of metastases to bone and lymph nodes however
contained ER- immunopositive carcinoma cells. In contrast to ER-p, ER- expression at
both protein and transcript levels was absent in all dysplasias but present in a few carcinomas
of the peripheral zone. The receptor was however expressed in metastases to two lymph
nodes and in the majority central zone dysplasias. AR expression remained consistently
strong in all grades of dysplasias and primary carcinomas as well as in metastases.
In sumary, we report that a downegulation of ER-p expreSSIOn occurs durng
prostatic carcinogenesis. This change may contribute to a loss in growth control processes
mediated by the p receptor which could amplify the effects of persisting proliferative stimuli
such as those mediated by AR.
The presence of ER-p as the predominant ER subtype in most metastases, together
with our recent findings that antiestrogens binding to the receptor inhibit proliferation of
prostate cancer cells (Lau et al 2000), may be useful in devising new ligand-specific
treatments for late stage disease.
C. MATERIALS AND METHODS
i. Generation of the GC17 polyclonal antibody:
The composition of the immunizing peptide used to generate the GC 17 rabbit anti
ER- antibody was selected with aid of the computer programs Protean (DNAST AR
, Inc.
Madison, WI) and Peptool (BioTools, Inc. , Edmonton, AB , Canada). A peptide sequence in
the F domain of the human ER- receptor (amino acids 449-465) was selected, as there is
no homology with estrogen receptor alpha (ERa) at this region (Mosselman et al 1996
Gustafsson 2000) . The peptide was custom synthesized by Research Genetics (Huntsvile
AL) with a format of 4-branch Multiple Antigenic Peptide. Each rabbit (male NZW
, 5-6 lbs)
was first inoculated with 0.5 mg peptide antigen with complete Freund' s adjuvant, and then
boosted with 0.25 mg peptide plus Incomplete Freund' s adjuvant at day 14, day 21 and every
two weeks afterward until a satisfactory seru titer was obtained. A direct Enzyme-Linked
ImunoSorbent Assay (ELISA) was used to assess the immune responses to the peptide
antigen (Harlow and Lane 1988).
ii. Methods used to test the specificity 
of the GC-17 antibody:
a) Competitive inhibition ELISA assay
The wells of an ELISA plate, PRO-BINtm (Becton-Dickenson Labware, Franklin
NJ) were coated with a recombinant protein composed of the entire ER-p sequence
(PanVera, Madison, WI) at a concentration of 5flg/mI. The GC17 antibody (1:6000) was then
pre-incubated with the immunizing peptide at concentrations ranging from 4mg-4flg/ml at
room temperature for 30 mins. In addition
, 4mg of a control peptide encompassing sequences
in the N-terminal region of ER-p (Research Genetics) was preincubated with the GC17
antibody (1 :6000) at room temperature for 1 h. The resulting antigen/antibody complexes
were then incubated with the bound recombinant ER-p protein on the ELISA plate at 37
for 2 Alkaline phosphatase conjugated anti-rabbit IgG antibody (J ackson
ImunoResearch, West Grove, PA) was used to recognize the GC17 antibody which bound
to recombinant ER-p protein on the plate. The whole complexes were visualized by
incubation with p-Nitrophenyl phosphate in 2-amino, 2-methyl, 1 propanediol buffer pH
6. Results were quantified by optical density using the Microplate reader 550 (Bio-Rad
Richmond, CA). The entire assay was done four times.
b) Competitive Immunohistochemistry
Lau et al (2000) have recently demonstrated that DU145 and LNCaP cells, both
derived from a metastatic prostate cancer, express abundant ERp mRA but not ERa
message. These cells were used to compliment and confirm that the GC- 17 antibody reagent
specifically detected ER-p but not ER-a by immunohistochemical staining. Using the GC-
antibody and the anti-ER-a antibody (NCL-ER-6F11 , Novacastra, Newcastle, UK) at the
same dilutions as for tissue sections (see below), we cared out immunohistochemical
studies on 10% formalin-fixed cytospins ofDU145 and LNCaP cells that had been routinely
processed, embedded in paraffn, sectioned at 5 flm and mounted on SuperFrost Plus TM slides
(VWF Scientific, West Chester PA).
We performed peptide competition studies at the immunohistochemical level that
approximated the conditions used in the ELISA assays described above. GC- 17 antibody, at a
dilution of 1 :6000, was incubated with the immunizing ER-p peptide at concentrations of 400
and 40flg at room temperature for 1h. In addition, competitive studies were conducted using
ER-a recombinant peptide (400 and 40flg, Affnity Bioreagents Inc., Golden, CO). on
DU145 cells. Incubation conditions and time were identical to those used for the ER-p
peptide competition studies. Deparaffinized sections of DU145 and LNCaP cells and human
prostate tissue were then incubated with these mixtures at room temperature for 1h.
Competition studies , done on prostate tissues , were identical to those performed on DU145
cells, except the peptide and antibody mixtures were incubated overnight and then applied to
sections for 24h at room temperature. All of the remaining immunohistochemical and other
staining procedures identical those used for tissue sectionswere (see
immunohistochemical procedures).
c) Western Blot Analysis
Four human normal prostate tissues from radical prostatectomies and one normal
human testis tissue were used in this analysis. In addition, we used normal prostate epithelial
cells (Clonetics, WalkersviIe, MD) and DU145 cells (ATCC, Rockville, MD) for these
studies. Recombinant proteins, ER-a (RP31O) and short form of ER-p (RP311) (Affinity
Bioreagents Inc. , Golden, CO) as well as long form ofER-p (Pan Vera, Madison, WI), were
included as controls. Tissues or cells were homogenized in radioimmunoprecipitation (RI A)
buffer containing 50mM Tris-HCl pH 7.4, 1 % Nonidet P-40 (Amaresco , Solon, OH), 0.
sodium deoxycholate, 0. 1 % SDS, 1mM phenoylmethylsulfonyl fluoride (PM SF) in
isopropanol, 1mM activated sodium orthovanadate and 2X CompleteTM proteinase inhibitor
cocktail (Boehrnger Maneim, Maneim, Germany). Twenty-five flg of tissue protein
extracts, 0.5flg of recombinant ER-a protein or 0.5flg of recombinant ER-p protein were
mixed with 2X SDS loading buffer (125mM Tris buffer pH 6.
, 20% glycerol, 2% SDS , 2%
p-mercaptoethanol and 1 flg/ml bromophenol blue) and electrophoresized onto a 10% SDS-
polyacrylamide gel under reducing condition. The separated proteins were transferred onto a
PolyScreen(B PVDF transfer membrane (NN, Boston, MA). The membrane was incubated
for 1 hr in blocking buffer (PBS with 5% nonfat dry milk). The primar antibodies were
applied at 1 :6000 for GC17 ER-p antibody or 1:5 for 1D5 ER-a antibody (Biogenex
Mountainview, California) in PBS- T (PBS with 0.05% Tween-20) buffer with 0. 1 % bovine
serum albumin for overnight at room temperature. After washing 5 times with PBS- T buffer
the membrane was incubated with horseradish peroxidase-linked donkey anti-rabbit IgG
antibody (Amersham Pharmacia Biotech, Piscataway, NJ) for GC17 or goat anti-mouse IgG
antibody (NN, Boston, MA) for 1D5 at 1 :2500 for 1 h. The signals were visualized with
chemiluminescence ECL detection system (NN, Boston, MA) and autoradiography. All
reagents were purchased from Sigma (St. Louis , MO) unless specified.
ii. Prostate tissues:
a) Formalin fixed radical prostatectomy specimens:
Tissues studied were from 50 radical prostatectomy specimens collected by JEM at
Stanford University Medical School, durng the years 1995 - 1999. Patients ranged in age
from 46-73 years of age and none had received any treatment prior to their undergoing
prostatectomy. Prostates were fixed in 10% buffered formalin for 24 h then sectioned
transversely. Tissues were dissected fixed in 10% buffered formalin for 3 h, routinely
processed, and embedded in paraffn. A histopathological diagnosis was made by JEM on a
hematoxylin and eosin stained (H&E). The criteria used in the grading of the carcinomas
were those described by Stamey et al (1999). The slide, together with the corresponding
paraffn block, was then sent to IL where immunohistochemical studies were carred out. 
least one section from each case was stained with H&E and reviewed by IL to assure that it
matched the tissue components in the original slide. Paraffn sections were cut at 6flm
mounted on SuperFrost Plus slides. Sections were left unbaked until used for
immunohistochemical studies.
Among the 50 cases selected for study, 26 contained areas of carcinoma. Five of these
were clear cell carcinomas of the transition zone while all the remaining cancers were found
in the peripheral zone. All of the peripheral zone cancers were composed of mixtures of
grade-3 and 4/5 carcinomas. In contrast, all of the clear cell carcinomas were predominately
grade-3 neoplasms. Twenty of the peripheral cancer specimens also contained varying
amounts of low/moderate to high-grade dysplastic lesions. Dysplasia of the peripheral zone
was found in the absence of carcinoma in 6 of the 50 total cases we studied. Additionally, 7
of the 50 cases, were low/moderate grade dysplasias of the central zone that did not coexist
with cancer. Among the 50 cases, two specimens each of lesion-free normal peripheral
central and the transition zone were included in our study. Among the cases studied, 15
examples .of benign prostatic hyperplasia (BPH) were either commingled with other lesions
(Ho et al 1997) or occurred separately (Leav et al 1978).
b) Bone and lymph node metastases:
In addition to the prostatectomy cases, archived paraffn blocks containing bone
metastases were obtained from 7 patients of MET, treated at University of Massachusetts
Medical Center. The patient' s ages ranged from 59-74 and they were all clinically stage D2
at the time of diagnosis. All received anti androgen treatment as follows: )Four patients were
orchectomized. One of these patients was given the LH/ agonist Lupron (TAP
Pharmaceuticals inc, Deerfield IL) and the AR competitive inhbitor Eulixin (Flutamide-
Schering corp. Kenilworth, NJ) for 3 months, one treated with Eulixin for 24 months and the
remaining two were not given any further anti androgenic therapy. 2)Three patients were not
orchectomized. Two were treated with Lupron for 8 months and the other with Lupron and
Eulixin for 3 months. Following these antiandogenic therapies for the periods noted above, it
was determined that all seven patients were failing therapy. At those time points, biopsies of
suspected bone metastases were obtained from the iliac crest of each patient. These samples
were immediately fixed in 10% buffered, routinely processed, embedded in paraffn, 6flm
sections placed on SuperFrostTM Plus slides , and stained with H&E. Replicate sections of
these lesions were used for immunohistochemical studies.
In addition, we also studied 5 archived examples of metastases to regional lymph
nodes. Two cases were obtained from Deparent of Pathology at University of
Massachusetts Medical School and the remaining 3 were from University of Florida Medical
School (a generous gift from Dr William Murhy). The patients were 60-85 years of age.
Regional lymph nodes (external iliac and pelvic) were obtained from all patients durng
radical prostatectomy. Only one patient had received any treatment prior to surgery (Lupron).
c) Frozen tissues for LCM/RT-PCR
Eighteen separate specimens, derived from radical prostatectomies, were placed in
cassettes containing TBS (Triangle Biomedical Sciences , Durham, NC) and quick-frozen in
liquid nitrogen by JEM and then shipped in dry ice to IL. Approximately fifteen minutes
elapsed from the surgical removal of the gland to the initiation of freezing. Formalin-fixed
and paraffn embedded tissue sections, immediately adjacent to the quick frozen specimens
were also taken for subsequent immunohistochemical studies (see below).
For diagnostic purposes and lesion selection, tissues were first cryostat sectioned and
then fixed briefly in 70% ethanol and stained with H&E. The frozen tissue blocks were then
stored at - C until they were used for microdissection. Prior to LCM, sections from these
cases were found to contain varying amounts of grade three and 4/5 carcinoma as well as
dysplastic and normal glands.
iv. Procedures:
a) Immunohistochemical procedures
The followings are the primary antibodies and the dilutions used in our studies:
Anti-estrogen receptor beta (ERP), rabbit polyclonal antibody GC17, diluted at
1 :6000; anti-estrogen receptor alpha (ERa), mouse monoclonal antibody NCL-ER-6F11
diluted at 1 :50 (Novocastra, Newcastle upon Tyne, UK); anti-androgen receptor (AR), rabbit
polyclona1 antibody, diluted to 22. g/ml (Upstate Biotechnologies, Lake Placid, NY); anti-
Mib5/K67 , mouse monoclonal antibody, diluted at 1 :50 (Imunotech, Westbrook, ME) and
anti-high molecular weight cytokeratin (HMWC), mouse monoclonal antibody 34pE12
diluted at 1 :50 (Enzo Diagnostics , Farmingdale, NY). Imunostaining for Prostatic Specific
Antigen (PSA) was done with a Nexus Imunostainer (Ventana, Tuscon Arz.) using
prediluted reagents.
Five m thick sections were cut and mounted on SuperFrost
TM Plus slides. Sections
were left unbaked until immediately prior to use at which point they were baked for 1 h at
C. After baking, sections were deparaffnized through three changes of xylene and
rehydrated through graded alcohols into water. Heat induced epitope retrieval (HIER) was
performed by boiling sections in citrate buffer pH 6.0 (pH 6.2 for ERP) for 15 min on a
laboratory hotplate. After boiling, sections were removed from the hotplate , allowed to cool
at room temperature (RT) for 20 min, and were then rinsed thoroughly with water (sections
stained for PSA did not require HIER). Sections were then placed in 3% hydrogen peroxide
for 15 min at RT to block endogenous peroxidase, washed with water, and placed in PBS
(Sigma, St.Louis, Mo). Sections were then incubated with Power Block (Biogenex)
nonspecific blocking reagent for 10 min at RT to reduce nonspecific staining, washed with
water, and placed in PBS. Sections were then incubated with normal goat seru at 1 :50
(Vector, Burlingame, CA) for 15 min at RT. The goat serum was then shaken off and
sections were incubated with primary antibodies overnight at 4 C. After overnght
incubation, each section received 20 sec of washing with PBS , 20 sec of washing with
Biogenex Optimax Detergent Wash Solution followed by 10 min of washing in PBS on a
rotator. Solutions were changed for every eight slides. Following washing, sections were
incubated with either Biogenex Mutlilink secondar antibody at a dilution of 1 :20 for 20min
at RT or DAKO (Carinteria, CA) ready to use secondary antibody for 10 min at RT.
Sections were again washed according to the protocol described above. Sections were then
incubated with either Biogenex Streptavidin-conjugated horseradish peroxidase at a dilution
of 1 :20 for 20 min at R T or DAKO ready to use streptavidin-conjugated alkaline phosphatase
for 10 min at RT. Sections were again washed as previously described. Imunostaining was
visualized using either Biogenex liquid 3 diaminobenzidine (Biogenex) or DAKOs New
Fuchsin as the chromogen. Following development, sections were rinsed in water, lightly
counterstained with 10% Hars Modified Hematoxylin.
Positive controls for GC- 17 included DU145 cells (see above and results section) and
tissue sections of prostate which were previously shown to be consistently stained with the
antibody. Positive tissue controls for ER-a were human breast cancers, shown to contain
numerous immunostained cells. Morphologically normal human prostate sections served as
positive controls for AR as well as for HMWC and MIB5/K-67 stains. For all reagents
negative controls were performed by substituting the primary antibody with a class-matched
isotype.
b) Laser capture microdissection and RT-PCR
In all instances, immunohistochemical studies for ER-p were performed on the
paraffn tissue sections which were adj acent to the frozen sections used for microdissection
and RT-PCR analysis. Frozen sections were cut on a cryostat at 5flm placed on precleaned
glass slides (Fisher Scientific , Pittsburgh P A) and immediately fixed in 70% ethanol for 5 s.
The sections were then briefly dipped in distiled water, stained with 10% Hars hematoxylin
for 15 s, dipped in distilled water, then successively placed in 70% ethanol for 30 s, briefly
immersed in 1 % eosin then placed in 95% ethanol 1 min, two changes of 100% ethanol 1 min
each, and two changes of xylene 30 s each. After air-drying for approximately 30 min tissues
were microdissected using a Pix cell 2 Laser microdissection unit (Arcturus , Mountainview
CA). Eight to ten normal acini were microdissected from each of 3 different cases. Similarly,
10-20 dysplastic glands were dissected from 4 separate cases of high-grade lesions, and
approximately the same numbers of neoplastic glands were obtained from 5 cases of grade 3
and six different examples of grade 4/5 carcinomas. RNA was extracted from each sample
and then separately subjected to RT-PCR analysis. Total cellular RNA was separately
isolated using RNA Stat-60 reagent (Tel-Test Inc. , Friendwood, TX) according to protocols
provided by the manufacturer. The total isolated cellular RNA was reverse-transcribed using
the GeneAmp RNA PCR kit (Perkin Elmer, CT) in tota120fll reaction mixture and 2fll of the
resulting cDNA was used in PCR on ER-a, AR and GAPDH and 3fll for PCR on ER-p. Hot
start PCR using AmpliTaq Gold DNA polymerase (Perkin-Elmer, CT) was employed in all
amplification reactions. The enzyme was activated by pre-heating the reaction mixtures at
C for 6 mins prior to PCR. The PCR programs were 45 cycles for GAPDH and 55 cycles
for ER-a, AR and ER-p of 1 min at 94 C, 1 min at 60 C (anealing temperature) and 1 min
at 72 C. This protocol was chosen to minimize non-specific product amplification. The
primer sequences for ER-a, AR and GAPDH were described in our previously study (Lau et
al 2000). The primer set for ER-p was newly designed and the forward primer is 5'
GATGAGGGGAATGCGTAGA-3 ' and the reverse pnmer
CTTGTTACTCGCATGCCTGA-3' .
D. RESULTS
i. Specificity of the GC-17 antibody:
a) Competitive ELISA
Pre-incubation of GC- 17 with the immunizing peptide (C-terminus of ER-p, ERBC)
successfully suppressed binding to the recombinant protein (Fig. 9). The suppression
occurred in a concentration-dependent maner when compared to the control where the
antibody was not pre-incubated with the immunizing peptide. In contrast
, pre-incubation of
GC- 17 with the control N-terminus peptide of ER-p (ERBN) did not significantly suppress
binding when compared with the control, indicating that the antibody was not cross-reactive
with this region ofthe ER-p protein.
b) Competitive immunochemistry
Strong nuclear immunostaining was detected in sections of DU145 and LNCaP cells
which served as positive controls for the peptide competition studies (Fig. 10
, panel A). Pre-
incubation of GC- 17 with either 400flg/ml or 40flg/ml of the immunizing peptide ERBC
totally abolished nuclear staining in sections of these cells, when compared with positive
controls where the peptide was omitted (Fig. 10
, panel B). Identical results were obtained
with sections of human (Fig. 10, panels C&D). In contrast, preincubation of GC17 with the
recombinant ER-a protein failed to block ER-p immunosatining of DU145 cells by the
antibody (data not shown). These studies confirmed that GC17 does not cross react with ER-
a and supports data from our Western Blot findings (see below). Thus, both the competitive
ELISA and competitive immunohistochemistry showed GC-17 to be highly specific for
binding to the ER-p protein.
In addition, DU145 and LNCaP cells, that only express ER-p (Lau et al 2000), were
negative when immunostained with the ER-a (NCL-ER-6F11) antibody. Positive staining of
prostate tissues with the ER-a antibody was restrcted to stromal cells (see
immunohistochemistr of normal prostate below).
c) Western Blot Analysis
Using Western blot analysis, GC17 was demonstrated to specifically recognize two
recombinant ER-p proteins and show no cross-reactivity to ER-a protein (Fig. 11 , panels A
and B). The size of recombinant ER-p protein (RP311) from Affinity Bioreagents Inc.
(Golden, CO) is approximately 53kDa and it represents a short form of ER-p protein using a
reported initiator codon (corresponding to 43-530 amino acids) (Kuiper et al 1996
Mosselman 1996, Tremblay et al 1997). The long form of ER-p recombinant protein
(Pan Vera, Madison, WI), containing 530 amino acids, was also recognized by GC17
antibody and showed a 59kDa band in the blot. A previous study demonstrated that the native
long form of ER-p protein in the cells is approximately 63kDa (Bhat et al 1998).
Interestingly, GC17 recognized an approximately 63kDa protein in human normal testis and
prostate tissues , suggesting that the long form may be the natural ER-p protein in human
tissues (Fig. lIb and 11 c). The size difference between long fonn of recombinant ER-p
protein and native protein in cells may be related to the occurence of post-translational
modifications in cells and tissues. The level of ER-a protein in human normal testis and
prostate tissues was undetectable with the 1D5 human antibody (Fig. 11a) for 30s exposure
to X-ray fim. However, very weak signal ofER protein can be detected only when the blot
was exposed to a X-ray film for over 10 mins.
ii. Immunohistochemistry of prostate tissues:
a) Normal prostate
In morphologically normal ducts and acini, nuclear ER-P expression was consistently
densely localized in nuclei of basal cells as defined by HMWC staining in replicate sections
(Fig. 12 , panels A & B). Strong nuclei staining was absent in secretory cells but frequently
observed in stromal cells. Occasionally nuclear membrane staining for the receptor was also
evident in a few luminal cells (Fig. 12, panels A & B). ER-a immunostaining was not
present in secretory cells of normal ducts and acini but individual scattered -receptor positive
basal cells were observed in less than 10% of all sections studied. The receptor was
however consistently found in stromal cell nuclei, especially in peri glandular locations.
Pronounced nuclear staining for AR was a constant finding in secretory and stromal
cell nuclei. In agreement with a past study (Leav et al 1996), varable immunostaining for
AR was also observed in individual basal cells of normal glands. No difference was found in
the cellular localization of the three steroid hormone receptors when the peripheral
transition, and central zones of the prostate were compared. Moreover, the same localization
of the steroid hormone receptors, found in the three normal zones, was also seen in foci of
BPH.
The most consistent immunolocalization for the three receptors in basal cells was
found within periurethral ducts.
b) Dysplastic lesions
Imunohistochemical findings in dysplastic and carcinomatous lesions are
summarzed in Table 1.
In the peripheral zone, a consistent pattern of ER-p expressIOn was found 
dysplastic lesions. A secretory cell localization for nuclear ER-p expression was commonly
observed in low to moderate grade dysplasitic lesions (Fig. 12 , panel C). The majority of
both basal and dysplastic secretory cells in these lesions, contained moderate to strongly
stained nuclei (Fig. 12, panel C). A marked diminution to total absence of ER-p
immunostained nuclei was a consistent feature in almost all dysplastic cells in the high grade
lesions we studied (Fig. 12, panel D). Staining was however present in residual basal cells
within these high-grade lesions. Thus, a loss of ER- staining in high-grade dysplasias
paralleled a decline in receptor-positive basal cells. In contrast to normal cells, the cytoplasm
of dysplastic cells in lesions of all grades but especially in high grade lesions were frequently
stained by the GC- 17 reagent, a feature not seen when the primary antibody was omitted
from the incubation or with the use of any of the other antireceptor reagents. Similarly
nuclear membrane of cells in high grade dysplastic cells also frequently stained with the GC-
17 antibody (Fig. 12, panel D). ER- positive dysplastic cells were not present within any
of the peripheral zone lesions we studied.
In marked contrast, ER- stained cells were detected in 5 of 7 (71 %) of dysplasias in
the central zone (Fig. 12 , panel E). There was however great varation in the numbers (10-
90%) of immunopositive cells in any given central zone lesion. In replicate sections, 6 of
these lesions contained dysplastic cells that were also positive for ER-p staining.
As previously reported (Leav et al1996), AR was strongly expressed in the majority
(:::.95%) of dysplastic cells irrespective of the origin or grade of the lesion.
c) Grade 3 and 4/5 carcinomas.
A transition from ER-p positive to negative staining of cells was observed in all 21
cases where cancer was found in the peripheral zone that paralleled the progression of the
grade 3 carcinomas to the less differentiated grade 4/5 neoplasms. ER-p positive cells were
found in 13 of 15 (87%) grade 3 carcinomas of the peripheral zone. The spectrum of
expression ranged from examples where all nuclei in an individual neoplastic gland were
strongly stained (Fig. 13 , panel A) to instances where receptor immunostaining was weak
and/or found in few cells within a given microscopic field. The latter examples were most
often located in areas where a transition to higher-grade carcinoma occurred (Fig. 13 , panel
B). Unlike their counterparts in the peripheral zone, the vast majority of cells comprising
grade 3 clear cell carcinomas in the transition zone were devoid of ER-p immunostaining. In
two of five cases, scattered receptor- positive neoplastic cells were however found in a
minority of glands (Fig. 13 , panel C).
Almost complete absence ofER-p nuclear staining was seen in all but 3 of 15 (20%)
grade 4/5 carcinomas (Fig. 13; panel C). In the majority of cases however staining of the
nuclear membrane was frequently apparent. In the 3 cases, positive cells represented only
10% or less of the total cancer cells in a given lesion and the staining intensity was usually
diminished.
Imunostaining for ER-a was detected in only two (7.6%) of the total twenty-six
cases of primary carcinoma we studied. In these 2 instances, a few (~ 10%) weakly positive
cells were found in both grades 3 and 4/5 carcinomas. Staining for the receptor was
consistently absent in all clear cell carcinomas of the transition zone.
Irespective of grade, strong nuclear AR immunostaining was a constant feature in the
vast majority cells ( 95%) comprising cancers of the peripheral zone. Nuclear AR
immunostaining was also present in almost all grade 3 clear cell carcinomas but it was less
intense than found in peripheral zone carcinomas. Interestingly, the occasional few cells that
were ER-p positive in these cancers were found to be negative for AR expression in replicate
sections.
No change in the location or intensity ofimmunostaining for the three receptors in the
stroma was evident in sections that contained carcinoma.
d) Metastatic lesions
Nuclear ER-p immunostaining was present in metastatic carcinoma cells in bone
lesions from all but one of the seven cases (Fig. 14, panel A). The intensity of signal did
however vary from strong to weak staining within cells comprising the lesions of individual
case and/or among the cases. In three instances, carcinoma cells were surounded by a
prominent desmoplastic response in which ER-p staining was frequently found in the nuclei
of fibroblasts. Nucleated hematopoietic marow cells were also positive for the receptor
while mature red cells were negative, a finding that served as a positive and negative internal
tissue control for ER-p immunostaining in these lesions.
In contrast to the finding of ER-p immunostaining in foci of all but one case of bone
metastasis, no staining was observed for ER- a in these lesions. Despite the fact that all of
seven patients, including the one that lacked ER-p expression had been given anti androgenic
therapy, nuclear AR staining was observed in most metastatic cells in the bone biopsies.
However AR staining was also consistently present in the cytoplasm as well as in the nucleus
of metastatic cells, a finding observed in bone and lymph node lesions from all patients who
received antiandrogenic therapy (see below).
PSA immunostaining was found in metastatic bone lesions in four cases but it tended
to be scant especially when compared to lesions in lymph nodes from patients who did not
receive antiandrogenic therapy (see following discussion).
Among the five cases of lymph node metastases, two contained a majority of
neoplastic cells ( 50%) that were uniformly strongly stained for ER-p (Fig. 14, panel B). In
one case immunostaining for the receptor was absent in the metastatic cells (Fig. 14, panel C)
while in the remaining two cases a mix of negative and positively stained neoplastic cells
were found. In one of the two cases , where strong receptor expression was detected, the
patient had been treated with the LH/ agonist Lupron prior to surgery. Lymphocyte nuclei
were consistently stained for the receptor and served as an internal positive tissue control in
the two cases where no receptor was detected in metastatic cells within the lymph nodes (Fig.
, panel B).
ER-a immunostained carcinoma cells were found in 2 of 5 cases of lymph node
metastases. Both patients were untreated prior to surgery. In one of these cases, ER-p
staining was absent in metastatic cells (Fig. 14, panel C). In one case, numerous a receptor
positive cells ( 50%) were mixed with those in which receptor expression was absent (Fig.
, panel D). Very weak staining for ER-a was identified in a few cells (~10 %) in the other
case.
In all five cases, AR immunostaining was present in the vast majority ( 95%) of
metatastatic cells (Fig. 14, panel E). Nuclear AR expression was always strong in cancer
cells and with the exception of the case where the patient received Lupron, cytoplasmic
staining was not present in any of the metastatic cells. Strong PSA immunostaining was
present in the cytoplasm of most metastatic cells in all cases including the one where the
patient had received antiandrogenic therapy.
ii. LCM/T-PCR analysis:
An example of a LCM specimen used in our study is seen in Fig. 15 (panels A&B)
Our findings with RT-PCR analysis for ER-p mRA on LCM lesions approximated
the results of immunohistochemical studies done on paraffin sections immediately adjacent
to the frozen specimens used for RT-PCR as well as on other cases (Fig. 15 , panel C). ER-p
transcripts were detected in 2 of the 3 samples of normal prostatic acini. In contrast, receptor
message was found in only 1 of 4 microdissected samples of high-grade dysplasias. Sixty
percent of grade 3 carcinomas contained ER- transcripts while receptor message was
detected in 2/6 (30 %) of the grade 4/5 cancers. In 2 cases where ER-p message was present
in grade 3 lesions, grade 4/5 carcinomas sampled within the same section, lacked receptor
mRA expression. In close agreement with our immunohistochemical findings, AR mRA
was present in all normal glands , dysplasias, grade 3 cancers and all but one of the grade 4/5
carcinomas. ER-a transcripts were not detected in any of the microdissected specimens we
studied.
E. DISCUSSION
In this study we developed and comprehensively demonstrated the specificity of a
novel antibody, prepared against the F domain of ER-p. Using this reagent, together with
antibodies for AR and ER-a, we immunolocalized the 3 receptors in normal human prostate
preneoplastic lesions , and carcinoma and in metastases. LCMlT-PCR was used to assess the
expression of the 3 receptors at the transcript level.
Using the GC- 17 antibody reagent, we now show that ER-p is predominately
immunolocalized in basal cells and to a lesser extent in stromal cells of the morphologically
normal human prostate. In addition nuclear membrane localization ofER-p was occasionally
observed in secretory cells. Our current studies have also confirmed past reports (Wernert et
al1988 , Schulze et al1990) that ER- a is detected in stromal cells and rarely in basal cells of
the normal gland. As previously reported (Leav et al1996 , Bonkoff et al1993, Gleave and
Chung 1995), we found that AR was predominately localized in the nuclei of differentiated
secretory cells and variably in basal cells of the normal acinar /duct unit as well as in stromal
cells. The finding of all three receptors in stromal cells is compatible with the concept that
they transduce steroid hormone signals to epithelial cells by paracrine mechanism (Gleave
and Chung 1995). In this regard, Hall et al (1999) have reported that ER- functions as a
transdominant inhibitor of ER- transcription and that it acts to decrease overall cellular
sensitivity to estradiol. Therefore the isoform, when colocalized with the receptor in
stromal cells, may playa critical role in regulating paracrine signaling from these cells to
epithelia. However the presence of ER-p as virtually the sole ER subtype in basal cells, the
purported precursor of secretory cells (De Marzo et al 1998), suggests that estrogens, acting
through the receptor, may directly modulate the growth of these cells. In this context, it
should also be noted that AR is variably expressed in basal cells (Leav et al1996, Bonkoff
et al1993). Thus , proliferative signals mediated by AR in basal cells or by ER-a and AR in
stromal cells may be opposed by the purported growth-inhibitory action of ER- (Chang and
Prins 1999, Krege et al1998 , Poelzl et a12000, Lau et a12000) localized in basal cells.
Prior to the discovery ofER-p (Leav et al 1978 , Merk et al1986) we reported that the
separate administration of androgens and estrogens to hypophysectomized and castrated dogs
induced marked proliferation of basal cells. Additionally, each hormone was found to direct
distinct pathways of cell differentiation culminating in either squamous cells with estrogens
or prototypic glandular cells with androgens (Merk et al 1986). Thus, while paracrine
stimulatory signals emanating from stromal cells likely contributed to these effects, the direct
action of the hormones mediated through their cognate receptors in basal cells may have also
played a role. In either case results from these studies indicate that basal cells are major
targets for the effects of steroid hormones in the prostate.
Mindful of these findings it was therefore of paricular interest to trace the expression
of ER- , normally localized in basal cells , and AR during prostatic cancer development and
progressIOn.
The transition from normal to low / moderate dysplastic glands in the peripheral zone
was marked by the appearance ofER-p homogeneously immunostained nuclei in secretory 
well as basal cells with no changes in the localization of the other receptors.
The expression of ER- was diminished in high-grade dysplasias when compared to
normal glands and lower grade lesions. Since the receptor is predominately localized in basal
cells in the normal gland, this finding is consistent with the reported depletion of these
receptor positive cells in the majority of high-grade dysplasias (Bostwick 1995). ER-p
staining was present in the majority of grade 3 carcinomas of the peripheral zone but was
greatly diminished or absent in most grade 4/5 carcinomas. Interestingly nuclear membrane
staining was evident in many cells in high grade dysplasias and grade 4/5 carcinomas. The
preCIse meamng of this finding is currently undefined but appears to represent the
localization of ER- that occurs with neoplastic progression and could reflect alteration in
receptor fuction. Recently, the promoter of human ER- gene has been cloned and showed
regions of CpG islands (Li et al 2000). The diminution of ER- expression in high-grade
dysplasias and grade 4/5 cancers may be therefore related to the alteration of DNA
methylation pattern in CpG islands of the promoter, resulting in down-regulation of the
receptor at the transcriptional level.
While the underlying mechanism(s) for these findings in dysplasias awaits fuher
investigation, based on the proposed antiproliferative function of the receptor (Chang and
Prins 1999, Krege et al 1998 , Poelzl et al 2000, Lau et al 2000), the presence of ER-p in
secretory cells of low/moderate grade lesions may represent a transient-abortive attempt to
counter growth of these cells. In contrast, the attrition of receptor positive basal cells in the
high-grade dysplasias may signfy a continuing loss of growth inhibitory fuction mediated
by ER- in these precursor lesions. The "reappearance" of the receptor in most grade 3
carcinomas and its possible effects on cancer growth is perplexing but may be related to the
more favorable prognosis reported for these well differentiated neoplasms (Stamey et al
1999).
Interestingly, in contrast to grade 3 carcinomas of the peripheral zone, expression of
the receptor was present only in a few scattered cells that comprised clear cell cancers of
the transition zone. The differences in receptor expression between the two grade 3
cancers likely reflect a distinct biology inherent in neoplasms with the clear cell phenotype.
While absent from peripheral zone lesions, ER-a staining was however found in
dysplastic cells in most lesions of the central zone. This finding may reflect suspected
biological differences (McNeal et al 1988a) as well as distinct pathways of hormone
responsiveness between the zones of the human prostate that could playa role in the
pathogenesis of these lesions. Interestingly, the central zone is rarely the site of origin for
prostate cancer (McNeal et al1988b).
Our findings of RT-PCR analysis for ER- mRA expression on microdissected
specimens approximated results from our immunohistochemical studies, indicating that
receptor expression was downregulated at both the transcriptional and translational levels in
high-grade dysplastic and 4/5 grade neoplastic lesions. Our findings in prostate therefore
differ from those reported for human colon cancer where Folley et al (2000) demonstrated
that a selective loss of ER-P protein but not receptor message expression occurs in these
neoplasms. These authors attributed the loss of ER- beta protein in colon cancers to be from
posttranscriptional modifications of the receptor.
In our study ER-a expression was limited to only a small subset of dysplastic lesions
in the central zone and to a very few primary carcinomas in the peripheral zone. Our findings
therefore differed from those of Bonkoff et al (1999) who found immunostaining for the
receptor in high- grade dysplasias and grade 4/5 carcinomas. Using in situ hybridization these
authors also reported that a high percentage of dysplasias and carcinomas in their study
contained cells that expressed ER-a message. These results again differed from our findings
as we did not detect ER-a message in any dysplasias or primary carcinomas we studied using
the highly sensitive and specific LCM/RT-PCR analysis.
Unlike ER-p, AR was consistently strongly expressed at both the transcript and
immunohistochemical levels, irrespective of grade, across the spectrum of preneoplastic
lesions and carcinomas we studied. These results are in agreement with our past studies of
AR in dysplasias 41 and those of others in both primary and metastatic carcinomas (Culig
2000). Importantly, results from a past study (Ruizeveld de Winter 1994) demonstrated the
presence of structurally intact AR that fuctionally binds androgen in the majority of both
hormone-dependent and independent carcinomas. Our curent findings , together with those
cited above, suggest that AR is expressed and fuctional in the majority of high-grade
dysplasias and primary prostate cancers. It is therefore possible that continued androgen
mediated stimulation of dysplastic and tumor cells, coupled with the apparent loss of ER-
expression, may enhance carcinogenic progression as well as the growth of established
prostatic carcinomas.
One of the most intriguing findings in our study was the high percentage of cases
(83%) where the expression of ER-p was present in prostatic carcinoma cells metastatic to
bone and regional lymph nodes. In marked contrast, ER- staining was absent in all but 2
cases where receptor positive cells were found in lymph node metastases.
While 58% of the patients with metastatic lesions in our study had been given
anti androgen therapy, positive staining for ER-p was also present in cancer cells within the
lymph nodes of three individuals that had not received this treatment. The presence of ER-p
in metastatic cells from patients who did or did not receive antiandrogenic treatment suggests
that blocking of androgen action was not a primary cause for the expression of the receptor in
these sites.
It is tempting to speculate that the new tissue microenvironment in which these
metastatic cells are found may have provided local factors that influenced the expression of
ER-P and to a lesser extent ER- a in these sites. In this context, it has been reported that bone
fibroblasts produced growth factors that induced human prostate cancer growth (Y oneda
1998). Alternatively, the metastatic process may, in some undefined maner, have favored
the spread of cells with either ER isoform from the primary cancer.
In summary, we demonstrate that a consistent pattern of lost ER-p expression at both
the transcriptional and translational levels occurs durng prostatic carcinogenesis and tumor
progression. This may signify the loss of an important role the receptor would normally play
in inhibiting growth of the prostate that could contribute to neoplastic development. The
continued expression of presumably functional AR throughout these processes, as well as
other undefined factors , may therefore exert persistent unopposed growth stimulus acting on
these cells.
The cause of ER expression and the effects that it may have on the growth of
metastatic cells remains to be defined. The presence of the p isoform in these cancer cells
may however have important ramifications for the treatment of patients with late stage
disease. In this regard, we recently reported that estrogens as well as antiestrogens are potent
growth inhibitors of human prostate cancer lines that express both estrogen receptor isoforms
(Lau et al 2000). In contrast, the growth of cells such as DU145 , which only express ER-P,
was markedly inhbited by the anti estrogen ICI 182 807. These findings together with results
from our curent studies may therefore be helpful in devising new ligand-specific strategies
for treating patients with metastatic prostate cancer.
CHAPTER V
ICI-182,780-, RAOXIFENE- AND RESVERATROL-INDUCED CELL GROWTH
INHIBITIONS IN PROSTATE CANCER AR ASSOCIATED WITH DOWN-
REGULATIONS OF TELOMERASE REVERSE TRASCRIPTASE, SURVIVIN,
AND THYMIDYLATE SYNTHASE mRA EXPRESSIONS.
A. ABSTRACT
Recent evidence suggests that ER-p may be an antiproliferative factor for a protective
effect against the mitogenic activity of estrogens in breast and androgens in prostate while
ER-a is involved in the estrogen-induced mitogenesis of breast epithelial and uterine cells.
We previously demonstrated that ICI-induced cell growth inhibition in DU145 cells is
mediated via ER-p actions. In this study, we investigated the mechanism of this inhibition in
DU145 cells. Flow cytometry data indicated that ICI-treatment could induce the
accumulation of cells at GO-Gl phase of cell cycle. With raloxifene, the treated cells also
showed this accumulation along with significant cell growth inhbition in DU145 cells.
Using real-time RT-PCR analyses on thymidylate synthase (TS), telomerase reverse
transcriptase (TERT), and survivin to semi-quantitate their transcript levels, this Go- cell
accumulation by ICI treatment is associated with the ICI-induced down-regulation of TERT
and surivin expressions. These down-regulations are dose-dependent and they appear to be
regulated by ER-p since the ICI-induced inhibition is mediated via ER-p actions. It had been
reported that the alterations in TERT and surivin decrease cell viability and prevent cells
from entering cell cycle. Therefore, the ICI-induced alterations of these gene expressions
may be a key factor in the observed cell growth inhibition in DU145 cells.
In addition, Rv treatment also exhibits inhibitory effects on cell growth of DU145
cells. A time course study showed that Rv had dual effects on the cell cycle distrbution 
the treated cells. In the early treatment (3 and 6h), there was accumulation of cells at GO-
phase. However, the treated cells were arrested at Sand G2/M phases after 12 and 24h
exposure to Rv. The transcript levels of TERT and surivin were also reduced by the Rv-
treatment, leading to prevent cell from entering cell cycle and decrease in cell viability. In
contrast to ICI-treatment, 1O- M Rv reduced TS transcript level in DU145 cells. The down-
regulation of TS may be related to the S and Gz/M cell cycle arests observed after longer
exposure to Rv which resulted in growth inhibition ofDU145 cells.
Taken together, our findings support the concept that ER-P participates in cell cycle
regulation in normal and malignant prostatic epithelial cells. Activation of the receptor by
anti estrogen and phytoestrogen induced cell growth inhibition and the mechanism may be
mediated by reduction of cell survival factors, leading to decrease in cell viability, and
induction of cell cycle arests.
B. INTRODUCTION
Estrogens modulate sexual development and reproductive functions in addition to
effecting the cardiovascular and central nervous systems and bone. Their effects are mediated
by at least two estrogen receptors, ER-a and ER-p (see reviews in Gustafsson 1999 and
Pettersson and Gustafsson 2001). Although they share high level (86%) of amino acid
homology in their DNA binding domains, the N-terminal and ligand binding domains are
different (23% and 58% homology respectively) and these domains contain transactivation
fuctional regions for recruiting coregulator proteins, suggesting 
that their biological
fuctions may be different (Mosselman et al 1996, Gustafsson 2000, Pettersson and
Gustafsson, 2001). The transactivation activities of these two receptors are promoter
dependent. At an activating protein 1 (AP-1) responsive element, 17p-estradiol increases
reporter activity with ER-a but inhibits it with ER-p. However, with the antiestrogens, the
activity decreases with ER-a and increases with ER-p (Paech et al 1997). In contrast
transactivation with two receptors at classical estrogen responsive element is similar between
17p-estradiol and antiestrogens (Paech et al 1997). In addition, tissue distributions of these
two receptors are different. In normal rat, ER-a expressed moderate to high levels in uterus
pituitar, ovary, kidney, epididymis, adrenal gland and cortical bone while high expression of
ER-p was found in prostate, ovary, lung, bladder, brain, uterus, testis and cancellous bone
(Kuiper et al 1997, Onoe et al 1997 , Ehrlich 2000). However, the functions of ER-p in
different tissues remain to be elucidated.
Expression of ER-p has been studied in varous types of human cancers such as
breast, colon, ovary and prostate (Vladusic et al1998 , Hu et al1998 , Roger et a12001 , Man
et al 2001 , Foley et a12000 , Campbell-Thompson et a12001 , Pujol et al1998 , Lau et al1999,
Rutherford et a12001 , Lau et a12000 , Lati et a12001 , Leav et a12001). In colon cancer, ER-
p was found to be down-regulated when compared to its level in normal tissue (Foley et al
2000, C ampb ell- Thompson et al 2001). With newly developed antibodies to ER-p, we and
others demonstrated that reduced expression of this receptor in proliferative preinvasive
mamar tuors (Roger et a12001) and in high grade of prostate cancers (Leav et a12001).
Since the reduction of ER-p expression is associated with increased Ki-67 staining that is a
cell proliferative marker, it has been suggested that the receptor subtype may have a
protective effect against the mitogenic activity of estrogens in premalignant lesions of the
breast (Roger et al 2001). This concept is supported by our finding that sole ER-p is
immunolocalized in basal cells of human normal prostatic acini which constitute the
proliferative epithelial cell compartent in the gland and are purorted precursor of secretory
epithelial cells. In addition, ER-p knockout mice have been reported to develop age-related
prostatic hyperplasia, which suggests that the receptor may act to inhibit abnormal growth of
prostate (Krege et al 1998). In this regards, ER-p was found to specifically interact with
MAD2 protein which functions as a cell cycle spindle assembly checkpoint protein (Poelzl et
al 2000). Taken together, these findings suggested that ER-p may be an antiproliferative
factor that curbs cell proliferation as part of a negative feedback system for cell cycle
regulation. Reduced expression of this receptor in cancers may result in the loss of this
negative feedback function, leading to uncontrolled cell growth.
In contrast to the down-regulation of this receptor in high-grade primary prostate
cancers, we found reactivation of ER-p expression in metastatic prostate cancer cells in
lymph node and bone (Leav et al 2001). All these bone metastases were obtained from
patients who had failed antiandrogen therapy. Although the mechanism involved in this
reactivation is unkown, we can take advantage of this phenomenon to design new treatment
for hormone refractory prostate cancer. Thus since ER-p may be an antiproliferative factor
the activation of the receptor by ligand binding may inhibit the growth of advanced stage of
prostate cancer. In our previous study, we demonstrated that antiestrogens such as 4-
hydroxytamoxifen and ICI- 182 780 (ICI) inhibited growth of androgen-independent prostate
cancer cells (DU145 and PC-3) (Lau et al 2000). With RT -PCR analysis and
immunocytochemistry, DU145 cells was shown to express sole ER-p (Lau et al 2000 , Leav
et a12001). This ICI-induced cell growth inhibition was considered to be mediated via ER-p
since the blockade of ER-p by antisense oligonucleotide can reverse the inhibitory effects of
antiestrogens (Lau et al 2000). These findings suggest antiestrogens may activate ER-p in
DU145 cells and hence induce antiproliferative effects.
Selective estrogen receptor modulators and phytoestrogens had been demonstrated to
bind effectively to ER-p (Kuiper et al1997 , Couse et al1997) but their biological effects on
prostate cancer remain to be elucidated. In this study, we explored the potential use of
raloxifene (Ral) and resveratrol (Rv) on inhibiting the growth of prostate cancer cells. In
addition, mechanisms of the effects of these compounds in advanced prostate cancer need to
be investigated. This provides invaluable information in further development of 
target-
specific drugs for this heretofore-incurable disease.
C. MATERIALS AND METHODS
i. Cell growth assay
DU145 (American Type Cultue Collection, Manassas , VA) are routinely maintained
in DMEM/F12 medium supplemented with heat inactivated fetal bovine seru (FBS), 2mM
glutamine, 1mM sodium pyrvate, 0. 1 M non-essential amino acids, 100 U/ml penicillin
and 100 flglml streptomycin (P/S), and 0.05 mM p-mercaptoethanol (Sigma Co. , St. Louis
MO). Cells were seeded at 2X10 cells per well in 96 wells-plates as day O. The cells were
allowed to attach for overnight in the culture medium as above except using 5% charcoal
strpped FBS and the medium was changed at day 1. The charcoal strpping removes
majority of steroids in serum. The medium also contains no phenol red, which had been
reported to have estrogenic properties. The cells were exposed to ICI, Ral, or Rv at 0. , 1 and
10 flM final concentration. Cells treated with empty vehicle (100% ethanol) were used as a
negative control. Freshly prepared medium with tested compounds was re-fed the cells once
at day 3. At the end of a 4-day treatment, cell numbers was assessed by direct cell count with
the Trypan blue exclusion method. For each treatment, triplicate wells were used and three
separated experiments were done. Statistical analysis wil be performed using SPSS program
(SPSS , Chicago, IL). Data were analyzed by one-way ANOV A, followed by the Tukey post-
hoc test, and a 95% confidence limit wil be used for all comparisons among treatment
groups.
ii. Determination of DNA content by flow cytometry
Cells were seeded at 5X10 cells per 75cm2 culture flasks as day O. The cells were
allowed to attach for 24h and the culture medium, as above except using 5% charcoal
stripped FBS, was changed at day 1. After 12h, the cells were exposed to ICI, Ral , or Rv at
- '
10 flM final concentration with freshly prepared medium supplemented with 5% charcoal
strpped FBS for 24h. Cells treated with empty vehicle (100% ethanol) were used as control.
Two milions of control or treated cells were fixed with 2 ml 70% ethanol for at least 24h at -
200C. The cells were stained in propidium iodide (PI) staining solution containing 1: 1
dilution of 20flg/ml PI in Hanks balance salt solution (Ca
2+ and Mg2+ free) and 1mg/ml
RNase A for 30 min at C. The stained cells were subjected to FACScan Analyzer
(Becton Dickinson Imunocytometry Systems, San Jose, CA) in our flow cytometry core
facility. In addition, a time-course experiment was performed on DU145 cells with Rv
treatment. Cells were prepared as above at different time points used (3 , 6, 12 , and 24h for
Rvand 1 , and 4 days for ICI).
ii. Analysis of DNA synthesis by bromo-deoxyuridine (BrdU) incorporation
Cells were seeded at 5X10 cells per 75cm
2 culture flasks as day O. The cells were
allowed to attach for 24h and the culture medium, as above except using 5% charcoal
strpped FBS, was changed at day 1. After 12h, pulse-chase experiments with BrdU were
performed and the cells were exposed to Rv at 10 flM final concentration with freshly
prepared medium supplemented with 5% charcoal stripped FBS for 12 , 18 and 24h. The
cells treated with empty vehicle (100% ethanol) were used as control for different time points
of treatment. After 6h of Rv treatment, BrdU was added to the medium to achieve a final
concentration of 10 flM. At the end of 12, 18 or 24h Rv treatment, 2X10 cells were
trysinized and washed twice with 1 % bovine serum albumin (BSA) (Sigma) in phosphate
buffered saline (PBS). The cells were suspended in PBS on ice and fixed with ice-cold 70%
ethanol. 2N hydrochloric acid with Triton X- 100 was slowly added to the fixed cells for
DNA denaturing. After centrifuge, the cell pellet was resuspended in O. lM sodium
tetraborate pH 8.5 to neutralize the acid and the cells were kept in 0.5% Tween 20/1%
BSAlBS before immunofluorescence staining with FITC-conjugated anti-BrdU (Becton
Dickinson, San Jose, CA). The cells were incubated with the antibody for 30 min at room
temperatue and washed once with 0.5% Tween 20/1 % BSAlBS. The BrdU labeled cells
were pelleted and resuspended in PBS with 50flg/ml RNase A (Promega) and 20flglml PI at
C. The stained cells were analyzed with a F ACScan Analyzer with laser excitation at
488nm.
iv. Real-time quantitative RT -PCR analysis
Cells were seeded at 5X10 cells per 75cm2 cultue flasks as day O. The cells will be
allowed to attach for 24h and the culture medium, as above except using 5% charcoal
stripped FBS , was changed at day 1. After 12h, the cells were exposed to ICI or Rv at 0.1 , 1
and 10 flM final concentration with freshly prepared medium supplemented with 5%
charcoal stripped FBS for 24h. Cells treated with empty vehicle (100% ethanol) were used
as control. Triplicate was set up for each treatment. Total RNA was isolated by TRI reagent
(Sigma) following manufacturer s recommended protocols. SYBR Green technology was
used for real-time quantitative RT-PCR analysis. One flg of total RNA was reverse-
transcribed using the GeneAmp RNA PCR kit (Perkin-Elmer, CT) and a SYBR Green PCR
Master Mix with AmpliTaq Gold enzyme (PE Biosystems, Foster City, CA) was employed.
Two fll of resultant cDNA was amplified in trplicate in a 25 fll reaction mixtue containing
12.5 fll of 2X SYBR Green PCR Master Mix , and 10 pmol of each primer. The intron-
spaning primers were designed using the Primer3 Output program from Whitehead
Research Institute , Massachusetts Institute of Technology, Cambridge, MA. The primers for
survivin, Telomerase reverse transcriptase (TERT), and thymidylate synthase (TS) were
I;,
shown in Table 4. The primer sets had been tested on genomic DNA and show no PCR
product to confirm that they are intron-spaning. Since the formations of primer-dimers and
non-specific PCR products significantly affect the accuracy of the assay, the melting cure
profie was obtained and the carefully optimized PCR condition and AmpliTaq Gold enzyme
(Perkin Elmer) for Hot-start PCR was used. The mRA expression of these ER-p regulated
genes was normalized by the expression of housekeeping gene (GAPDH) for all the
comparisons. The integrty of total RNA samples also was determined by the analysis on this
housekeeping gene.
D. RESULTS
i. Inhibition of DU145 cell growth by ICI, Rv and Ral
Cell growth analyses showed that the growth of DU145 cells, which only expressed
ERp (Lau et al 1999, Leav et al 2001), was adversely effected by ICI, Ral and Rv. The
inhbitory effect ofICI on DU145 cell growth had been reported in our previously study (Lau
et al 1999). Both Ral and Rv induce a dose-dependent cell growth inhibition (Figure 16). A
60% reduction 
(p 
~ 0.001) in the cell numbers was achieved with an Rv dose of 10 flM
(Figue 16A). A similar growth-inhibitory response was observed when DU145 cells were
treated with Ral (60% reduction p ~ 0.001) (Figure 16B). At 1 flM, Rv induced approximate
20% inhibition 
(p 
~ 0. 05) on DU145 cell growth while 40% 
(p.
001) for Ral. For the Ral
treatment, the concentration at 0. 1 flM can also induce statistically significant inhbitory
effects on DU145 cell growth 
(p 
~ 0.001).
ii. Induction of cell cycle arrest by ICI, Ral and Rv
The cell cycle distrbutions, which are based on the DNA content of cells, of control
and treated cells were presented in Table 5. After 24h treatment of 10 flM ICI, the
percentage ofDU145 cells at GO- phase of cell cycle increased 
(p:: 
001) when compared
to those of control. Similarly, treatment of Ral also induced cell cycle arrest at GO- phase
(p 
:: 0.001). In contrast, the percentage of Rv-treated cells at S 
(p
:: 0.001) and Gz
(p 
01) phases showed statistically significant increase.
Cell cycle distributions in DU145 cells at various time points after exposure to ICI
and Rv were analyzed (Figures 17 A and 17B). After the exposure to Rv for 3 and 6 the
percentage of cells at GO- phase was higher than that of the control cells. There was a
reduction of the Rv-treated cells at S phase and even no cell was found in the GzM phase.
However, at 12h Rv treatment, the majority of cells were demonstrated at the S phase while
the percentage of cells at GO- phase was the same as the control cells and still no cells in
the GzM phase. After 24h Rv treatment, the cells at Sand G2M phases predominates the cell
populations in the culture (Figure 17 A). In contrast, the treatment of ICI induced
accumulation of GO- cells throughout the 4 days exposure (Figure 17B). With the slightly
increase in the percentage of cells at GO- phase in the control cells with time, the degree of
induction of GO- cell accumulation by ICI treatment decreased.
To fuher investigate the effects of Rv on DU145 cells, the pulse-chase experiments
with BrdU incorporation were performed (Table 6). After 12h Rv treatment, the percentage
of cells at the mid S phase was higher than that of the control cells. As time progress (18h),
the cells at the late S phase showed high percentage in the cell population of cultue with Rv
treatment when compared to those in the control. At 24h, the high percentages of cells at
three (early, mid, and late) S phases was found in the Rv treated cell population.
In summary, treatment of ICI and Ral on DU145 cells induced the accumulation of
GO- cells while Rv treatment increased the percentage of GO- cells in population in the
early phase of the treatment and arrested the cells at S-phase of the cell cycle in the
prolonged treatment.
ii. Effects ofICI and Rv treatments on thymidylate synthase, TERT, and survivin
mRNA expression
To examine the effects ofICI and Rv on gene expressions ofTS , TERT , and survivin
real-time RT-PCR analysis was used to semi-quantitate their transcript levels in treated cells
relative to the control. Treatment ofICI for 24h in DU145 cells reduced TERT and survivin
.:--- -
mRA expressions at three different concentrations (10- , 10- and 10- M) (Figure 18B and
18C). These downregulations were dose-dependent. In contrast, the level of TS in the ICI-
treated cells was comparable to those in the control (Figure 18A). For Rv, treatments for 24
hat 10- and 10- M downregulated TERT and surivin in DU145 cells (Figure 18E and 18F)
while the treatments at these two doses induced a trend of reduction in transcript level of TS
(Figue 18D). Interestingly, 10- M Rv treated cells expressed comparable transcript levels of
TS and TERT to those in the control (Figue 18D and 18E). The level of survivin mRA in
these treated cells did not further reduce at 10- M R v treatment compared to those at 10-
although the reduction by 10- M R treatment was still statistically significant when
compared to those in the control (Figure 18F).
E. DISCUSSION
We previously reported that antiestrogens such as ICI and 4-hydroxytamoxifen
exhibit growth inhibitory effects on DU145 cells that express sole ER-p. This anti estrogen-
induced cell growth inhibition can be reversed by the blockade of ER-p with antisense
oligonucleotide, suggesting that it may be mediated via ER-p actions (Lau et al 2000).
Potentially, the findings may lead to development of new treatment for hormone-refractory
metastatic prostate cancer where ER-p expression was found as DU145 cells (Leav et al
2001). In this study, we revealed the mechanism of this inhibition and demonstrated that ICI
can induce accumulation of cells at GO- phase of cell cycle. It suggests ICI treatment
reduces cell viability as well as prevents cell cycle entry which results in inhibition in cell
proliferation. This may be related to our findings that the treatment of ICI in DU145 cells
downregulated both TERT and survivin expressions.
Telomerase is a ribonucleoprotein complex containing template RNA, telomerase-
associated protein and reverse transcriptase subunit (TERT) responsible for de novo telomere
synthesis and addition of telomeric repeats to existing telomere (Greider 1995). TERT was
found to be a rate-limiting determinant oftelomerase activity (Meyerson et al1997, Xu et al
1999). Its activity had been demonstrated to be in high level in the majority of human
cancers and negative in many normal tissues. Interestingly, telomerase activity had also been
detected in the normal basal layer of epidermis, where most proliferation occurs (Yasumoto
et al1996 , Harle-Bachor et al1996) and in the normal oral mucosa that is highly proliferative
tissue (Kannan et al 1997). In addition, using isogeneic samples of cultured and uncultured
human uroepithelial cells and transitional cell carcinomas, telomerase activity had been
demonstrated to associate with cellular proliferation and not cellular transformation in human
uroepithelial cells. The activity was detected in proliferating mammary and 
prostate
epithelial cells (Belair et al 1997). These findings supported the concept that telomerase
activity is a cell proliferation factor. Disruption of telomere maintenance by alterations in
TERT expression and telomerase activity limits cellular lifespan in human cancer cells (Hahn
et al 1999). Recent studies have shown that downegulation of TERT by 
antisense
oligonucleotide in DU145 cells can decrease cell viability and inhibit cell growth (Schindler
et a1 2001). These indicate TERT expression is essential to the growth of DU145 cells and
the ICI-induced reduction ofTERT mRA may contribute to the growth inhibitory effects of
this compound on DU145 cells.
Surivin is a member of the family of inhbitors of apoptosis (lA) and localized to
the components of the mitotic apparatus (Li et al 1998). It is involved in both inhibition of
apoptosis and control cell division (Reed and Bischoff 2000). Interference with survivin
expression/functio using antisense or a dominant negative mutant caused spontaneous
apoptosis in keratinocytes (Grossman et al 1999). In addition to induction of apoptosis, the
antisense to survivin in HeLa cells decreased cell viability and the number of proliferating
cells at G /M phase, resulting in inhibition of cell growth (Ambrosini et al 1998).
Overexpression of surivin was found in varous cancers including prostate but its level was
undetectable in almost all normal tissues. The high level of survivin in cancer cells leads to
prolong cell viability and may contribute to cancer by facilitating the insurgence of mutations
(Thompson et al1995 , Ambrosini et al1997). Although surivin is an inhibitor of apoptosis
its expression is correlated to proliferation index but not apoptosis index in hepatocellular
carcinoma (Ito et al 2000). It promotes cell proliferation by interacting with cycle-dependent
kinase 4 and releasing p21 from this kinase (Ito et al 2000). Moreover, survivin had been
suggested to initiate cell cycle entry (Suzuki et al 2000). Overexpression of surivin can
accelerate S phase shift and induce resistance to G cell cycle arest through activation of
cdk2/cyclin E complex leading to retinoblastoma protein phosphorylation (Suzuki et al
2000). Therefore, the down-regulation of survivin by ICI treatment may prevent cell
entering into cell division. However, our flow cytometry data indicate no significant
induction of apoptosis by ICI even though the level of survivin was reduced. It may be due
to the facts that DU145 cells express mutated p53 protein (Isaacs et al 1991) and survivin is
involved in p53-dependent apoptosis (Grossman et a12001).
In this study, we demonstrated that Rv exhibited cell growth inhibitory effects on
prostate cancer cells in agreement with the previous reports (Hsieh and Wu 1999, Mitchell et
al1999). These studies showed down-regulation of prostate-specific antigen by Rv treatment
in LNCaP cells and suggested that Rv can modulate androgen-stimulatory growth of the cells
(Hsieh and Wu 1999, Mitchell et al 1999). However, growth of DU145 cells is androgen-
independent and Rv-induced growth inhibition in this cell line is not mediated via androgen
receptor associated pathway. In addition, it has been reported that Rv induced apoptosis in
LNCaP cells while the 4-days treatment in DU145 cells showed a trend of accumulation of
cells at S phase (Hsieh and Wu 1999). Our flow cytometry data showed that Rv-treatment in
DU145 cells can induce statistically signficant cell cycle arrest at S phase after 24h
exposure. In the time course study, Rv induced accumulation of cells at GO- phase in the
early treatment (3 and 6h). The prolong treatments (12 and 24h) cause DU145 cells arested
at S and Gz/M phases. Rv-treatment apparently exhibits dual effects on cell cycle
distribution in DU145 cells.
Treatment of Rv in DU145 cells also down-regulated expression of survivin. Since
surivin initiates cell cycle entry (Suzuk et al 2000), the accumulation of Go- cells in the
early treatment may be due to Rv-induced prevention of cells into cell cycle. Interestingly,
the higher dose (10- M) of Rv-treatment did not further reduce the level of survivin
transcripts and the degree of reduction was similar to those by 10- and 10- M dose. After
24h exposure to 10- M Rv, a large portion ofthe cell population was arrested at S and Gz
phases. Expression of survivin shows cell cycle periodicity and these cells express high level
of survivin (Li et al 1998). It increases by 6 folds in S phase and by more than 40 folds in
/M phase (Li et al 1998). The increased amount of S and Gz/M cells together with high
levels of survivin in 10- M Rv-treated cell populations apparently prevented the further
down-regulation of the gene by Rv. A similar phenomenon was also found for TS in Rv-
treated DU145 cells. Previous studies have reported that the activity of TS is highest during
S phase (Navalgund et al 1980, Ayusawa et al 1986, Mitjolet et al 1998). TS is a key
enzyme in nucleotide metabolism and catalyzes the methylation of deoxyuridine
monophosphate to deoxythymidine monophosphate in the presence of the cofactor N
methylenetetrahydrofolate. This reaction is the sole 
de novo source of thymidylate for DNA
synthesis (Pinedo et al 1988). Inibition of TS by fluorouracil can induce S phase arest in
colon (Backus et al 2001) and also prostate cancer cells (Cattaneo-Pangrazzi et al 2000).
Down-regulation of TS mRA and protein by antisense oligonucleotide also inhibits cell
proliferation (Ferguson et al1999). Berg et al (2001) have recently shown that the inhibition
is due to accumulation of cells at Gz/M phase. The down-regulation of TS by Rv-treatment
may therefore also contribute to the accumulation of cells at S and Gz/M phases and inhbit
cell growth in DU145 cells. The Rv-induced DU145 cell growth inhibition may also have
been due to the reduced expression ofTERT in the treated cells as was the case for the ICI-
treatment. In consistent with this concept, Schindler et al (2001) have reported that the
disruption of telomere maintenance decreases cell viability and inhibits cell growth.
Recently, Rv was found to directly interact with DNA polymerases a and cS and inhibit DNA
synthesis (Stivala et al 2001). With this curent finding, the enzyme activities of these two
isoforms of DNA polymerases warant fuher study in Rv-treated DU145 cells.
We found that ICI-treatment can down-regulate TERT and survivin mRA
expressions in DU145 cells and Rv can modulate the levels of TS, TERT and survivin
transcripts in these cells which expressed only ER-p. Together with our finding that ICI-
induced cell growth inhibition is mediated via ER-p actions (Lau et a12000) and that Rv and
ICI binds to estrogen receptors (Gehm et al 1997 , Bowers et al 2000), these genes may be
regulated via ER-p. In concert with our findings, TS, TERT, and survivin were down-
regulated by tamoxifen in colon cancer cells which also only express ER-p (Nakayama et al
2000). In fact, telomerase activity is believed to be under hormonal control in prostate
(Meeker et al1996). Moreover, estrogen can up-regulate TERT mRA expression in MCF-
7 and human ovarian epithelial cells which express estrogen receptors. However, in the cells
without estrogen receptor such as MDA-MB231 and HeLa cells, estrogen showed no effect
on expression of this gene (Kyo et al1999, Misiti et a12000). Similarly, TS expression can
be induced by estrogen and even tamoxifen in MCF-7 cells (Aitken and Lippman 1985
Aitken et al 1985) for the G1 /S progression (Xie et al 2000). These findings supported that
they may be ER-p regulated genes.
In conclusion, our findings support the concept that ER-p may be antiproliferative
factor in agreement with the recent report that ER-p inhibits proliferation and invasion of
breast cancer cells (Lazennec et al 2001). Activation of the receptor with antiestrogens and
phytoestrogens inhibits prostate cancer cell growth and the mechanism may be mediated by
reduction of potentially ER-p-regu1ated cell survival factors such as TERT, survivin and TS,
leading to decrease in cell viability and induction of cell cycle arests.
CHAPTER VI
CONCLUSION
In this study, we provide evidence that normal human prostatic basal epithelial cells
express ER-p but not ER-a. It suggests that estrogens in human prostate act directly on the
epithelial cells via their own receptor, instead of the paracrine regulation by ER-a in the
stromal cells. These findings warrant further study in the biological involvements ofER-p 
human prostate physiology.
To investigate ER-p expression in human clinical prostate samples , we had developed
an ER-p antibody and characterized this antibody extensively to demonstrate its specificity.
Results indicated that ER-p expression is down-regulated in high-grade dysplasia compared
to the low-grade lesions. The down-regulation was also found in high-grade prostate
cancers. Recently, reduced expression of this receptor was demonstrated in proliferative
preinvasive mammary tuors (Roger et al 2001). Since the reduction of ER-p expression is
associated with increased Ki-67 staining that is a cell proliferative marker, it has been
suggested that the receptor subtype may have a protective effect against the mitogenic
activity of estrogens in premalignant lesions of the breast (Roger et al 2001). This concept is
supported by our finding that sole ER-p is immunolocalized in basal cells of human normal
prostatic acini which constitute the proliferative epithelial cell compartment in the gland and
are purported precursor of secretory epithelial cells. In addition, ER-p knockout mice have
been reported to develop age-related prostatic hyperplasia, which suggests that the receptor
may act to inhibit abnormal growth of prostate (Krege et al1998). In this regards , ER-p was
found to specifically interact with MAD2 protein which functions as a cell cycle spindle
. '
. H
assembly checkpoint protein (Poelzl et al 2000). Taken together, these findings suggested
that ER-p might participate in cell cycle regulation that curbs cell proliferation as part of a
negative feedback system for cell cycle regulation. Reduced expression of this receptor in
primary cancers may result in the loss of this negative feedback function, leading to
uncontrolled cell growth.
However, ER-p is widely expressed in the metastatic prostate cancer using our newly
developed antibody for immunohistochemistry. It is in agreement with the findings of RT-
PCR analysis on prostatic carcinoma cell lines. DU145 and LNCaP cells was shown to
express exclusively ER-p while PC-3 cells expressed both ER-a and ER-p transcripts.
Mechansms for this reactivation of ER-p in metastatic cancers and its biological
signficances in prostatic metastasis remain unown. Signoretti and Loda (2001) speculated
that metastatic prostate cancers seem to display a basaloid phenotype. Many genes expressed
by the basal cells, such as bcl-2 (McDonnell et al1992, McDonnell et al1997, Colombel et
al1993), Her-2-neu (Signoretti et a12000) and prostate stem cell antigen (Reiter et al1998),
are reactivated in metastatic cancers and ER-p may be one of them (Signoretti and Loda
2001). Role of ER-p in metastatic prostate cancer cells remains unown and should be a
focus of further investigation.
The positivity of androgen-independent metastatic prostate cancer for ER-p could
lead to development of new therapy for this late-stage of disease since this receptor may be
an antiproliferative factor. Two androgen-independent prostate cancer cell lines, DU145 and
PC-3 cells , were found to exhibit dose-dependent cell growth inhibition by antiestrogen (ICI
and 40H-TAM) treatments. Moreover, blockade of ER-p using antisense oligonucleotide
reduced the ICI-induced inhbition in DU145 cells, suggesting that the cell growth inhibition
by ICI is mediated via ER-p actions. Based on our findings , ICI was proposed to treat the
patients with advance prostate cancers and the clinical trial will be performed in University
of Massachusetts Medical Center, Worcester, Massachusetts in collaboration with
AstraZeneca Pharmaceuticals LP (Wilmington, DE).
Selective estrogen receptor modulators and phytoestrogens had been demonstrated to
bind effectively to ER-p (Kuiper et al 1997 , Couse et al1997) but their biological effects on
prostate cancer remain to be elucidated. In this study, we explored the potential use of
raloxifene (Ral) and resveratrol (Rv) on inhbiting the growth of prostate cancer cells and
found that both effectively inhibit DU145 cell growth and the inhibition is dose-dependent.
Treatments of ICI and Ral induced cell cycle arrest at GO- phases. The GO- phases cell
cycle arrest by ICI is associated with the down-regulation of survivin and telomerase reverse
transcriptase (TERT). These down-regulations are dose-dependent and they appear to be
regulated by ER-p since the ICI-induced inhibition is mediated via ER-p actions. It had been
reported that the down-regulation of TERT and survivin decrease cell viability and prevent
cells from entering cell cycle (Schindler et al 2001). Therefore, the ICI-induced alterations of
these gene expressions may be a key factor responsible for holding cells in GO-G 1 phases of
cell cycles in DU145 cells.
Rv has duel effects on cell cycle distrbution depending on the duration of treatments.
After 3 or 6 hrs treatment of Rv, the cells were arrested at GO- phases. The prolonged
treatment of Rv induced S-phase cell cycle arrest. The transcript levels of TERT and
surivin were also reduced by the Rv-treatment, leading to prevent cell from entering cell
cycle and decrease in cell viability. In contrast to ICI-treatment, 10- M Rv reduced TS
transcript level in DU145 cells. The down-regulation of TS may be related to the Sand
/M cell cycle arrests observed after longer exposure to Rv which resulted in growth
inhibition ofDU145 cells.
In conclusion, ER-p plays significant roles in the normal physiology of human
prostate and the genesis and progression of the cancer. This receptor may be antiproliferative
factors that curbs cell proliferation as part of a negative feedback system for cell cycle
regulation in the organ. Down-regulation of the receptor is involved in prostatic
carcinogenesis. In addition, ER-p in advanced prostate cancer may be potential target of new
drug design for this heretofore-incurable disease.
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Figure 1. Hypotheses of estrogen actions on prostate (A) Indirect action: Estrogens bind to
ER in stromal cells and the complexes transactivate gene expressions of growth and
differentiation factors which act on basal and glandular epithelial cells. (B) Direct and
indirect actions: Estrogen actions are mediated via ERa in stromal cells as described above.
In addition, estrogens directly act on epithelial cells via ERp associated pathway.
Figure 2. ER acts at an ERE by binding both DNA and co activators (Kushner et al 2000).
ER-tmgn actates at aUm:oQtf!
resnse elements by triggering
C0Nators
Figure 3. DBD independent and AF dependent pathway for estrogen-ER activation of AP-
Junos recruit CBP-p160s, and ER binds to the co activators and trggers them to higher
activity (Kushner et al 2000).
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Figure 4. DBD dependent and AF independent pathway for tamoxifen-ER activation at AP-
1. ER-tamoxifen located away from the AP- 1 site (for example, on non-specific DNA) binds
a complex of N-CoR and HDACs through the DBD-hinge-LBD. This draws away HDACs
that are associated with the AP- 1 site and allows unopposed activity of HATs in coactivators
recruited by Junos (Kushner et al 2000).
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Figure 4. Results of RT-PCR analyses of ERa, ERp, PR, pS2 and AR mRAs among
normal and malignant prostatic epithelial cells. Total RNAs were extracted and reverse-
transcribed. The resultant cDNAs were subjected to PCR analyses under optimized
conditions. The amplified products were run into 2% agarose gel with eithidium bromide.
Three individual experiments were performed. (A) Representative fluorographs for ERa
ERp, PR, pS2, AR and GAPDH RT-PCR analyses. (B) An excerpt from ERa fluorograph
enlarged to illustrate the exon 2 deletion variant of ERa (ERaL'2) in PC- 3 cells. (C) A
sumary of the data from RT-PCR analyses performed in three individual experiments (+
detectable level of expression; undetectable level of expression).
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Figure 5. Reactivation of ERa and pS2 mRA expressIOns m DU145 cells by
demethylating agents. Cells were treated with either 2.5 flM (AI) or 5 flM (A2) 5' -aza-
cytidine, or 0.5 flM (D1) or 0.75 flM (D2) 2' deoxy- -aza-cytidine for 8 days. Cells
without treatment were used as control (N. At the end of treatment, total RNA was
extracted and subjected to RT -PCR analyses as described in Figure 1.
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Figure. 6. Effects of anti estrogens and estrogens on cell growth of DU145 cells. Cells (5 x
cells/well) were plated in triplicate wells onto a 24-well plate. After 24 h for cell
attachment, cells were treated for 4 days with anti estrogens ICI and 40H-TAM) or
estrogens (C, Ez and DES) at various concentrations as indicated. Cells treated with
vehicle (absolute ethanol) were used as control. The number of viable cells at the end of 4
days of treatment was determined by the trypan blue exclusion method. Three individual
experiments were performed. Columns means; bars SD; = 9; * ~ 0.001 compared with
control (!I.
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Figure 7. Effects of antiestrogens and estrogens on cell growth ofPC-3 cells. Cell growth
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Figure 8. Reversal of ICI-induced DU145 cell growth inhibition by ERp antisense ODN.
Cells were treated with ICI at 10- M in the absence or presence of 2.5 flM of the antisense
sense or mismatch ODNs for 4 days. Cell numbers in "untreated" cultures received no ICI
treatment were arbitrarly assigned a value of 100% (first histogram on the left). Cell
numbers in cultures treated with ICI and ICI plus ODNs were expressed as percentages of
cell numbers in the "untreated" cultures. Histograms= means , bars=S. , n = 16. * denotes
significant difference between ICI treated cultues and those received ICI plus the antisense
ODN atp ~ 0.001.
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Figure 9. Competitive ELISA. This graphic representation ilustrates the concentration-
dependent competition of the immunizing peptide (ERPC) with the GC-17 antibody. In
addition, preincubation with 4 mg/ml of the control N-terminus peptide (ERpN) and GC-
failed to compete 9ut the binding to the recombinant ER-P peptide, demonstrating the
specificity of the antibody. The GC-17 antibodies , bound to recombinant ER-P protein on
ELISA plates, were recognized by alkaline phosphatase-conjugated anti-rabbit IgG
antibodies. The whole complexes were visualized by incubation with p-nitrophenyl
phosphate. The optical density at 405 nmol/L was measured. The entire assay was done four
times. The colum represents the mean value of optical density at 405 nmol/L of four
measurements and the bar represents the SD. w/o , GC- 17 preincubated without peptide
antigen.
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Figure 10. Competitive ER-p imunostaining DU145 cells (A and B) and normal prostate
(C and D). A: DU145 cells immunostained in the absence of competing peptide are shown.
Note the strong nuclear staing in the majority of cells (original magnfication, x265). B:
Afer incubation of GC-17 with 40 flg of the imunzing peptide, there was alost a total
absence of cells with positively stained nuclei (compare with A) (original magnfications:
xl15 (left), x350 (right)). C: Tissue section of normal prostate. In the absence of competing
peptide strong imunostainig of cells in the basal layer of glands is seen in ths section of
prostate (see also Figue 4, A and B) (original magnifications: xl15 (left), x230 (right)). D:
A replicate section of the prostate ilustrated in C afer preincubation of GC- 17 with 40 flg of
imunzing peptide. Note the absence of immunostaing in these sections (original
magnfications: x90 (left), x280 (right)). For details of the procedures used in these studies
see Materials and Methods. All sections were counterstained with 10% Hars hematoxylin.
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Figure 11. Western blot analysis. These autoradiographs ilustrate the binding ability and
specificity of GC- 17 to ER-p protein and its lack of cross-reactivity with ER-a protein. A
and B: Shown from left to right 
are the ER-arecombinant protein, short form of ER-p
recombinant protein, and tissue 1ysates from human testis and normal prostate (1 to 4). C:
From left to right are cell 1ysates of PrEC and DU145 cells, tissue lysates from human
normal prostate (1 and 2), and long form of ER-p recombinant protein. The recombinant
proteins and cell or tissue lysates were separated with SDS-P AGE gel and the separated
proteins were transferred onto PolyScreen polyvinylidene difluoride transfer membrane. The
blot was incubated with the ER-a monoclonal antibody (A) or GC-17 ER-p polyclonal
antibody (B and C) and the complexes were visualized by the chemiluminescence ECL
detection system. Note that the antibody detects only the ER-a protein using ER-a
monoclonal antibody and GC-17 ER-p polyclona1 antibody does not detect the ER-a 
protein
but clearly identifies single bands for both forms of ER-p recombinant proteins and for the
cell or tissue lysates. These bands correspond to the reported size of the short and long forms
of the receptor (see Results).
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Figure 12. A and B: Immunolocalization of ER-p in the normal human prostate using the
GC-17 antibody. Note the strong staining of cells in the basal layer and its virtal absence in
the nuclei and cytoplasm of secretory cells (best seen in B). Some nuclear membrane staning
was however evident in a few secretory cells (A and B). Nuclear stainig is also evident in
stromal cells. Original magnfications: x100 (A), x400 (B). C: ER-p imunostanig 
low/moderate-grade dysplasia. Moderate to strong expression of the receptor is evident in
dysplastic secretory cells. Note also the strongly stained cells in the basal layer (original
magnfication, x400). D: ER-P-imunostained section of high-grade dysplasia. Nuclear
stanig is almost totally absent in this lesion. In some dysplastic cells light staining of
110
nuclear membranes is evident. This area of the lesion is almost totally devoid of receptor-
stained basal cells. A few stained basal cells are however evident in the 
bottom left corner of
the lesion. Note the presence of two positively stained basal cells in a portion of a normal
gland on the right (original magnification, x250). E: ER-a immunostaining in dysplasia of
the central zone. The majority of dysplastic cells are immunostained for the receptor in this
lesion. There was however great variation in the percentage of positive cells found in these
central zone lesions. Intraluminal pseudo-gland formation seen here was common in
dysplasias of the central zone (original magnification, x200). All sections were
counterstained with 10% Hars hematoxylin.
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Figure 13. A: ER-p stainig in grade 3 carcinoma. Strong nuclear immunostaining is evident
in ths grade 3 carcinoma. Light cytoplasmic staining of neoplastic cells is also present.
Although positive immunostaning for the receptor was found in the majority of grade 3
cancers there was varation in the percentage of stained cells in any given lesion. Ths was
especially the case in areas of transition ITom grade 3 to grade 4/5 carcinoma (see C)
(original magnfication, x400). B: ER-p imunostaing of a clear cell carcinoma in the
transition zone. Imunostainig for the receptor is absent in the majority of cells in ths
grade 3 clear-cell carcinoma. Scattered among the negatively stained cells are cells with
small nuclei that are immunopositive for the receptor. The occurence of these positive cells
was uncommon in clear cell carcinomas. In most of these cancers all of the cells were
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unstained for the receptor. Interestingly, in replicate sections, these ER-p-positive cells were
negative for AR immunostaining whereas the reverse was tre for the majority of cells that
were negative for the p receptor (original magnfication, x400). All sections were
counterstained with 10% Hars hematoxylin. C: ER-p staining in an area of transition from
grade 3 to grade 4/5 carcinoma. The majority of nuclei in this cancer are unstained. A few
positively stained nuclei are however seen in two grade 4/5 glands (bottom left) and in a
single cell in a grade 3 gland (bottom right). Light cytoplasmic staining is evident in most
cells. Nuclear membrane staining is also present in many of these cells. Cytoplasmic staining
was common in all grades of dysplasia and carcinoma. Nuclear membrane immunostaining
was however only a featue of high-grade dysplasias and grade 4/5 carcinoma (original
magnification, x400).
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Figure 14. A: ER-p imunostang in a prostatic carcinoma metatatic to bone. Note the
strong nuclear immunostaining for the p receptor in ths metastatic lesion. The neoplastic
cells are localized between spicules of bone. Strong to moderate staining was present in the
majority of metastases to bone (original magnfication, x400). B: ER-p imunostainng in a
prostatic carcinoma metastatic to an internal iliac lymph node. Strong nuclear
immunostaining is evident in ths metastatic lesion. Strong PSA immunostaning of these
cells were found (not ilustrated). Note that the nuclei of several stromal cells in ths lymph
node are also positively stained for the receptor (original magnfication, x400). C: ER-p
immunostaining of a prostatic carcinoma metatatic to a lymph node. In this example the
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metastatic cells were unstained for the receptor. Cells in this same cancer were however
immunostained for ER-a and AR (see D and E). As was the case for the metastasis
illustrated in B these cells were strongly PSA-positive. Note that lymphocytes are strongly
stained for the receptor, which was a consistent finding and provided an internal positive
control for immunostaining with the p antibody (original magnification, x100). D: ER-a
immunostaining of the same lesion ilustrated in C. Imunopositive cells are seen scattered
throughout this metastatic lesion. In one other case of lymph node metastasis a very few
positive cells (~10%) were present. ER-p was however strongly expressed in that metastatic
lesion. Note the absence of ER-a immunostaining of lymphocytes, a consistent finding that
was in contrast to ER-p staining in these cells (original magnfication, x100). E:
Representative section of AR immunostaining in metastatic lymph node lesions. Strong
nuclear staining was uniformly found in the majority of cells that comprised these metastatic
lesions. Cytoplasmic staining occured only in metastases from the patient who had received
anti-androgenic therapy. Lymphocytes were lightly stained for AR (original magnfication
x100). All sections were counterstained with 10% Harrs hematoxylin.
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(A) (B)
Figure 15. A and B: LCM dissection of a grade 3 carcinoma. A: The grade 3 neoplastic
gland that was microdissected is seen in the center of this microscopic field (original
magnification, x325). B: The microdissected lesion is seen on the transfer cap (original
magnification, x325). Both sections were lightly stained with 10% Harrs hematoxylin. C:
Results ofRT-PCR analysis ofER-p mRA on microdissected human normal prostate acini
(N-1 and N-2) and grade 3 (G3-1 and G3-2) and 4/5 (G4-1 to G4-) carcinomas. Total
RNAs were extracted from the microdissected tissues on transfer cap and reverse-transcribed.
The resultant cDNAs were subjected to PCR analyses. The amplified products were ru into
2% agarose gel with ethidium bromide. Representative fluorographs for ER-p and GAPDH
RT-PCR analyses are shown.
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Figure. 16. Rv- and Ral-induced cell growth inhbition in DU145 cells. (A) Inibitory
effects of Rv on growth of DU145 cells. (B) Inibitory effects of Ral on growth of DU145
cells. Cells were seeded at 5X10 per ml of culture medium in 24 wells cultue plates. 
hours after plating, the cells were treated with 10- , 10- and 10- M of Rv. Control cultures
are treated with vehicle alone (0. 1 % ethanol as final concentration). At the end of a 4-day
treatment, cell numbers were assessed by direct cell count with the Trypan blue exclusion
method. Columns = group means; error bars 
= S. = 18 cultures; # denotes signficant
difference at ~ 0. 05 and * at ~ 0.001 when compared to untreated control.
117
(A)
a. 60
go 50
(B)
-a 70
2j 40
'0 30
D. 
phase
-E 60
!; 50
'0 30
N' 20
D. 0
S phase
.t.
120
M phase
.r 
.- 
15 18 
Exposure time (h)
M phase
---,::--
120
Exposure time (h)
3 6 12 15 18 21 24
Exposure time (h)
phase
a. 40
$. 30
N' 15
c: 10
D. 0
3 6 12 15 18 21 24
Exposure time (h)
S phase
a"-. ..a.
.. ." 
Figure 17. Cell cycle distributions in DU145 cells at various time points after exposure to Rv
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(A) and ICI (B). DU145 cells were treated with 10 flM Rv for 3 , 6 , 12 , and 24h and ICI for
, 48 , 72, and 96h (7). The cells with 0. 1 % ethanol as final concentration were used as
controls for each time point (,). At various time points, cells were fixed, stained with PI, and
subjected to flow cytometry for determination of cell cycle distribution.
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Figure 18. Results of Real-time RT-PCR analyses ofthymidylate synthase (TS), TERT and
survivin on DU145 cells treated with 10- , 10- and 1O- M ICI (A-C) and Rv (D-F) for 24 h.
The signals of TS , TERT and survivin were normalized by the signal of GAPDH and the
relative abundance was used for all the comparisons. 
Columns = means; error bars = S.
= 3; * denotes significant difference atp ~ 0.05 when compared to control.
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Table 1: Primer sequences or ana IVSIS
Target gene Primer sequence
Location Expected Size
ERP ER!3- 1 :5' TGA AAA GGA AGG TTA GTG GGA ACC3'
nt.230-253 528 bp
ER!3-2:5' TGG TCA GGG ACA TCA TCA TGG3' nt.737-757
ERa ERa- l:5' TAC TGC ATC AGA TCC AAG GG3'
nt.41- 650 bp
ERa-2:5' ATC AAT GGT GCACTG GTT GG3' nt.671-690
PR- l:5' GATTCA GAA GCC AGC CAG AG3' nt.817- 1836 533 bp
PR-2:5 ' TGC CTC TCG CCT AGT TGA TT3' nt.2330-2349
pS2 PS2- 1:5' GGA GAA CAA GGT GATCTG CG3'
nt.52- 236bp
PS2-2:5' CAC ACT CCT CTT CTG GAG GG3' nt.268-287
AR- l:5' CTC TCT CAA GAG TI GGA TGG CT3' nt.2896-2918 342 bp
AR-2:5 ' CAC TTG CAC AGA GAT GAT CTC TGC3' nt.3214-3237
GAPDH GAPDH-F:5' CCA CCC ATG GCA AAT TCC ATG GCA3'
nt.52- 175 598 bp
GAPDH-R:5 ' TCT AGA CGG CAG GTC AGG TCC ACC3' nt.726-749
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Table 2: Oligonucleotide sequences for the antisense ODN experiments
Target gene Sequences
Location Size
ERP
Antisense * CAC AGC AGG GCT A
15 to +3 18 bp
Sense
* AGC CCT GCT GTG AMismatch
* CTC AGC ACG GCA A
* This base was phosphorothioate-modified.
(g The first base of translation-initiating site is + 1.
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Immunohistochemical findings in dysplasias and carcinomasER-a ER-pTable 3:Lesion
lasia / Peri heral zone
Moderate grade
High grade
lasia /Central zone
Carcinoma! Peri heral zone
Grade 3
Grade 4/5
Carcinoma! Transition zone
Metastatic carcinoma
Lymph nodes -
/++ 
* Data reflects positive staining in dysplastic and basal cells. Staining restrcted to residual
basal cells in high-grade dysplasias. + = Positive staining in )-50% of cases; -/++ = Positive
staining in 40% of cases; -/+ = Positive staining in~ 20% of cases. See text for estimates of
the % of positively stained cells in each lesion.
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Table 4: Primers for Real-Time RT-PCR analysis on survivin, TERT, thymidylate synthase
(TS), and GAPDH
Genes Primer sequences Size
1. Survivin F: 5' GATGACGACCCCATAGAGGA- 187bp
R: 5' GCACTTTCTTCGCAGTTTCC-
2. TERT F: 5' MCTTGGCGGMGACAGTGGT- 241bp
R: 5' CMGACCCCMAGAGTTTGC-
3. Thymidylate synthase F: 5' TCCCGAGACTTTTTGGACAG- 206bp
R: 5' CMGCGCACA TGA TGA TTCT -
5. GAPDH F: 5' GGMGCTCACTGGCATGGC- 70bp
R: 5' - T AGACGGCAGGTCAGGTCCA-
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Table 5: Percentages of cells at different phases of cell cycle after treatment of ICI, Ral, or
Rvat 10 flM for 24h
Treatment for 24h
Control 56.61 :10. 33.78 +0. 61 +0.
ICI 66.52 :10. 25.83 +0.41 64 :10.46
Ral 63.83 :10. 27.89 :10. 28 :10.
26.25 :11. 50.54 :10. 23.21:2.
* Mean of percentages for 3 separated experiments :t standard deviation
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Table 6. Results of pulse-chase experiments with BrdU incorporation for treatments of Rv at
varous time points.
Duration of treatment Total S phase Early S phase 
(%)
Mid S phase 
(%)
Late S phase 
Control - 12h 43.74 13.63
22.40
Rv - 12h 66. 15. 29.
22.
Control - 18h 56. 43. 10.
Rv -18h 67. 28. 11.
29.
Control- 24h 49. 24. 13.99 11.
Rv - 24h 69. 33. 18.
18.
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